[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 523
1. Mazeron JJ, Simon JM, Toubiana T, Lang P: [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate]. Bull Cancer; 2005 Dec;92(12):1078-84
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non metastatic adenocarcinoma of prostate].
  • [Transliterated title] Hormonoradiothérapie des adénocarcinomes non métastatiques de la prostate.
  • Non metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormono therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16396754.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


2. Hallemeier CL, Kohli M, Chandan VS, Miller RC, Choo R: Multiple urinary bladder masses from metastatic prostate adenocarcinoma. Rare Tumors; 2010 Dec 31;2(4):e65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple urinary bladder masses from metastatic prostate adenocarcinoma.
  • We present an unusual case of metastatic prostate adenocarcinoma that manifested with multiple exophytic intravesical masses, mimicking a multifocal primary bladder tumor.
  • Biopsy with immunohistochemical analysis confirmed metastatic prostate adenocarcinoma.
  • This case illustrates that when a patient with known prostate cancer presents with multifocal bladder tumors, the possibility of metastatic prostate cancer should be considered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2000 Jan;36(1):32-40 [10632749.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):379-88 [10802363.001]
  • [Cites] Hinyokika Kiyo. 2001 Oct;47(10):747-9 [11758360.001]
  • [Cites] J Urol. 1955 Oct;74(4):498-521 [13264313.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] J Natl Cancer Inst. 2009 Sep 16;101(18):1280-3 [19713548.001]
  • [Cites] Hinyokika Kiyo. 2010 Feb;56(2):123-5 [20186001.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Urol Int. 1994;53(1):50-2 [7974888.001]
  • [Cites] Ann Diagn Pathol. 2007 Dec;11(6):413-6 [18022125.001]
  • [Cites] Lancet. 2009 Jan 24;373(9660):301-8 [19091394.001]
  • [Cites] Radiother Oncol. 2009 Nov;93(2):192-6 [19464745.001]
  • (PMID = 21234257.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019600
  • [Keywords] NOTNLM ; prostatic neoplasms / radiotherapy. / urinary bladder neoplasms
  •  go-up   go-down


3. Primavera V, Querques G, Guigui B, Turco I, Iaculli C, Russo V, Delle Noci N: [Choroidal metastasis from clinically regressed prostate adenocarcinoma: imaging of a rare case]. J Fr Ophtalmol; 2008 Nov;31(9):877-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Choroidal metastasis from clinically regressed prostate adenocarcinoma: imaging of a rare case].
  • [Transliterated title] Métastase choroïdienne d'un adénocarcinome de la prostate: iconographie d'un cas rare.
  • We report a rare case of prostatic adenocarcinoma metastases at the choroids, diagnosed and followed by fluorescein angiography (FA), indocyanine-green angiography (ICGA), and optical coherence tomography (OCT-3 Stratus).
  • The systemic workup, including hematologic analysis and total-body computed tomography (CT), revealed elevated serum prostate-specific antigen (PSA) and alkaline phosphatase, extensive abnormalities of the axial skeleton, and nodular pulmonary shadows; therefore, prostatic adenocarcinoma was suspected.
  • Needle biopsies (prostatic and pulmonary) confirmed adenocarcinoma of the prostate, with metastatic disease.
  • DISCUSSION: Prostatic carcinoma should be considered in any male patient with a choroidal mass suspected of being a metastasis.
  • In our patient, FA, ICGA, and OCT clearly documented the complete regression of choroidal metastasis from prostatic carcinoma.
  • Fluorescein angiography, indocyanine-green angiography, and optical coherence tomography are useful tools in the diagnosis and follow-up of prostatic adenocarcinoma metastatic to the choroid.
  • [MeSH-major] Adenocarcinoma / secondary. Choroid Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107059.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Veshapidze N, Alibegashvili M, Gabunia N, Ramishvili L, Kotrikadze N: Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate. Georgian Med News; 2009 Jan;(166):9-12
Hazardous Substances Data Bank. SODIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate.
  • The aim of our study was to investigate the alterations of the erythrocyte membrane permeability in the men with metastatic adenocarcinoma of the prostate before and six months after castration.
  • For experimental research were used the erythrocytes of 15 men with metastatic prostate cancer (Pca) (before and after 6 months from castration) and of the 15 practically healthy men (control group).
  • Investigations revealed the changes of Na(+)/K(+)-ATP-ase activity and the changes of Na(+) and K(+) ions concentration in metastatic Pca patients before and six months after castration.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Membrane Permeability / physiology. Erythrocyte Membrane / metabolism. Prostatic Neoplasms / metabolism. Sodium-Potassium-Exchanging ATPase / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19202209.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 9NEZ333N27 / Sodium; EC 3.6.3.9 / Sodium-Potassium-Exchanging ATPase; RWP5GA015D / Potassium
  •  go-up   go-down


5. Veshapidze N, Chigogidze T, Managadze L, Gabunia N, Kotrikadze N: Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy. Georgian Med News; 2007 Dec;(153):11-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamics of the structural and electrical characteristics of erythrocytes in men with metastatic adenocarcinoma of the prostate before and after plastic orchiectomy.
  • The changes of electrophoretic mobility of erythrocytes in the practically healthy men and in men with metastatic prostate cancer before and after castration were studied.
  • Investigation revealed, that the level of electrophoretic mobility of erythrocytes was decreased in the blood of metastatic prostate cancer patients (before castration), as compared with control group and with post operational period data.
  • It was found, that during the malignant adenocarcinoma of prostate (before and after surgery) pathological changes in organism effect erythrocytes superficial membranes and alter their electrical and structural parameters.
  • Probably, that is one of the reasons of considerable decrease of erythrocytes electrophoretic mobility in patients with metastatic prostate adenocarcinoma (before castration).
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Erythrocytes / metabolism. Erythrocytes / ultrastructure. Orchiectomy / methods. Postoperative Care. Preoperative Care. Prostatic Neoplasms / secondary. Prostatic Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18250488.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


6. Brandon ML, Odom SR, Barone JE, Waxberg JA: Adenocarcinoma of the prostate metastatic to the testis via lymphatic invasion: a case report. Conn Med; 2005 Feb;69(2):69-70
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the prostate metastatic to the testis via lymphatic invasion: a case report.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Testicular Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779601.001).
  • [ISSN] 0010-6178
  • [Journal-full-title] Connecticut medicine
  • [ISO-abbreviation] Conn Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Yin M, Dhir R, Parwani AV: Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma. Diagn Pathol; 2007;2:41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.
  • BACKGROUND: Immunohistochemical detection of prostate specific antigen (PSA) is widely used to identify metastatic prostatic adenocarcinoma.
  • However, PSA may not be expressed in some poorly differentiated prostatic carcinomas and its immunoreactivity has been found in some non-prostatic tissues.
  • P501s (prostein) is a prostate-specific marker that is expressed in the cytoplasm of benign and malignant prostatic glandular cells.
  • The purpose of this study was to evaluate the expression of P501s in metastatic prostatic adenocarcinoma and compare its expression with PSA.
  • The TMA is constructed with normal donor prostates (NDP), prostatic adenocarcinoma (PRCA), non-neoplastic prostatic tissues adjacent to malignant glands (NAT), benign prostatic hyperplasia (BPH), high-grade prostatic neoplasia (PIN), metastatic adenocarcinoma to lymph nodes (MLN), metastatic adenocarcinoma to other sites (MC), and samples of benign testis, colon, adrenal and kidney.
  • The two groups of metastatic lesions were also subjected to stains with antibodies to PSA.
  • Although the metastatic lesions demonstrated similar rate of negative expression with PSA antibody, only 2 MC cases (3.3%) showed simultaneous negative stains for both P501S and PSA.
  • CONCLUSION: P501s is an organ specific marker for benign and malignant prostatic epithelial cells.
  • Its characteristic cytoplasmic stain pattern provides an additional valuable immunomarker for detection of metastatic prostatic malignancy, even though the intensity of its expression is reduced, as in the case with PSA.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 1999 Jul;56(2):169-76 [10573109.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1563-8 [11245466.001]
  • [Cites] Hum Pathol. 2003 Jul;34(7):646-53 [12874759.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2202-6 [14562378.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1034-40 [14997204.001]
  • [Cites] Eur J Immunol. 2004 Apr;34(4):1091-101 [15048720.001]
  • [Cites] Prostate. 2004 Aug 1;60(3):246-56 [15176054.001]
  • [Cites] J Clin Pathol. 2005 Jan;58(1):69-71 [15623486.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2006 Sep;263(9):872-4 [16830117.001]
  • [Cites] Urol Res. 1990;18(3):181-7 [1697709.001]
  • [Cites] J Mol Histol. 2007 May;38(2):113-21 [17318343.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):599-603 [17425391.001]
  • [Cites] Eur Urol. 1985;11(2):91-4 [2408895.001]
  • [Cites] Clin Exp Metastasis. 1985 Apr-Jun;3(2):103-10 [4042459.001]
  • [Cites] Am J Clin Pathol. 1984 Mar;81(3):279-84 [6199966.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1721-9 [7523719.001]
  • [Cites] J Urol. 1993 Mar;149(3):510-5 [7679754.001]
  • [Cites] J Urol. 1996 Aug;156(2 Pt 1):464-8 [8683704.001]
  • [Cites] Prostate. 1997 May 1;31(2):91-7 [9140121.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2256-61 [9610707.001]
  • [Cites] Diagn Cytopathol. 1998 Sep;19(3):221-5 [9741000.001]
  • [Cites] Diagn Cytopathol. 2000 Sep;23(3):199-201 [10945910.001]
  • (PMID = 17963516.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2174437
  •  go-up   go-down


8. Tohfe M, Baki SA, Saliba W, Ghandour F, Ashou R, Ghazal G, Bahous J, Chamseddine N: Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature. Cases J; 2008;1(1):316

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate adenocarcinoma presenting with pulmonary symptoms: a case report and review of the literature.
  • INTRODUCTION: Prostate cancer has a high tendency to spread to bone.
  • Few patients with prostate cancer present initially with symptomatic metastatic lung lesions and lymphadenopathy without any other concomitant distant dissemination.
  • Despite the absence of any detectable osseous lesions and with the presence of multiple hilar, mediastinal, para-aortic, and pelvic lymphadenopathy, the patient had a complete work-up in search for the primary adenocarcinoma.
  • His prostate specific antigen was 146 ng/ml and a prostatic biopsy done, revealing an acinar prostatic adenocarcinoma.
  • A tru-cut biopsy of a lung lesion under computed tomography guidance showed a metastatic prostatic adenocarcinoma positive for prostate specific antigen stain.
  • CONCLUSION: This case sheds light on an unusual metastatic pattern of prostatic adenocarcinoma.
  • It also emphasizes the importance of including prostate cancer in the differential diagnosis of men with adenocarcinoma of unknown origin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):216-9 [16678051.001]
  • [Cites] Urol Int. 1998 Oct;61(1):17-21 [9792977.001]
  • [Cites] Cancer. 1995 Jun 1;75(11):2706-9 [7743474.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1990 Apr 15;65(8):1843-6 [2317763.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Radiology. 1985 Mar;154(3):601-4 [2578678.001]
  • (PMID = 19014682.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2590613
  •  go-up   go-down


9. El Khatib K, Moufid K, Abouchadi A, Nassih M, Rzin A: [Maxillary metastasis revealing a prostate cancer]. Rev Stomatol Chir Maxillofac; 2007 Nov;108(5):468-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Maxillary metastasis revealing a prostate cancer].
  • [Transliterated title] Métastase maxillaire révélatrice d'un cancer de prostate.
  • CASE: A 57 year-old-man presented with a maxillary tumor which proved to be an adenocarcinoma.
  • The prostate was hard and PSA were high.
  • Biopsy confirmed the diagnosis of metastatic prostatic adenocarcinoma.
  • DISCUSSION: Facial bone metastases are rare comparatively to the high metastatic incidence in the rest of the skeleton.
  • [MeSH-major] Adenocarcinoma / secondary. Maxillary Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17881024.001).
  • [ISSN] 0035-1768
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


10. Shine NP, O'Sullivan P: Collet-Sicard syndrome: a rare presentation of metastatic prostate adenocarcinoma. Auris Nasus Larynx; 2005 Sep;32(3):315-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collet-Sicard syndrome: a rare presentation of metastatic prostate adenocarcinoma.
  • Metastatic spread of prostate adenocarcinoma to the temporal bone is rare.
  • A case of metastatic prostate adenocarcinoma involving the temporal bone causing a Collet-Sicard syndrome associated with an ipsilateral lower motor facial palsy and a mixed sensorineural and conductive hearing loss is presented.
  • This case highlights the potential of prostate adenocarcinoma to cause symptoms referable to the temporal bone region and histopathologic analysis of biopsy material should include immunohistochemical staining for prostate specific antigen.
  • [MeSH-major] Adenocarcinoma / secondary. Cranial Nerve Diseases / etiology. Prostatic Neoplasms / pathology. Skull Neoplasms / secondary. Temporal Bone

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15885949.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Sheridan T, Herawi M, Epstein JI, Illei PB: The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol; 2007 Sep;31(9):1351-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
  • BACKGROUND: Adenocarcinoma of the prostate can present as metastatic carcinoma with no known primary.
  • Prostatic origin can be confirmed in most of these cases by immunohistochemistry for prostate-specific antigen (PSA) and prostate-specific acid phosphatase.
  • In a small subset of high-grade prostate carcinomas, both markers are negative and therefore are not helpful for confirming prostatic origin.
  • Recently, novel marker proteins that are preferentially expressed in prostate tissue were identified.
  • It is expressed in both benign and neoplastic prostate tissues, but not in any other normal or malignant tissue examined to date.
  • Owing to its apparent specificity, prostein may be a good marker to demonstrate prostatic origin in metastatic prostate cancer.
  • The tissue microarray contains 78 cases of metastatic prostatic adenocarcinoma, 20 cases of primary prostatic adenocarcinoma, and 20 cases of benign prostate tissue from the peripheral zone as well as samples of benign brain, pancreas, kidney, thyroid, testis, skeletal muscle, and fibroconnective tissue.
  • RESULTS: Similar staining (intensity and extent) was identified for both markers in the majority of metastatic tumors (11 distant sites, 42 pelvic lymph nodes), in all 20 primary tumors and in all benign prostate and nonprostate tissues.
  • In summary, 67 of the 69 cases (97%) of metastatic prostate carcinomas were PSA positive, whereas 68 of the 69 cases showed at least focal weak reactivity for P501S (99%).
  • CONCLUSIONS: Immunohistochemistry for P501S is a sensitive and highly specific marker for identifying prostate tissue.
  • The large majority of metastatic prostatic adenocarcinomas are P501S positive (99%).
  • A small subset of metastatic prostatic adenocarcinoma shows significant differences in staining intensity and extent for PSA and P501S and, therefore, combined use of these markers may result in increased sensitivity for detecting prostatic origin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Membrane Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721190.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / prostein; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


12. Cortés González JR, Garza R, Martínez R, Gómez L: [Prostate adenocarcinoma metastatic to penis]. Actas Urol Esp; 2006 Sep;30(8):832-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate adenocarcinoma metastatic to penis].
  • [Transliterated title] Adenocarcinoma de próstata metastático a pene.
  • Prostate cancer is a disease that appears with a very high frequency.
  • We present one case of a patient with painless metastatic nodules on the penis secondary to a prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Actas Urol Esp. 2006 Oct;30(9):962-4 [17175940.001]
  • (PMID = 17078582.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 6
  •  go-up   go-down


13. Ponz-Sarvisé M, Calvo A, Redrado M, Nguewa PA, Abella L, Catena R, García-Foncillas J, Panizo A, Gil-Bazo I: Inhibitor of differentiation-1 (Id1) characterization in poor-prognosis (PP) human bladder cancer (BCa) primary tumors and matched metastases (MTS) using a new monoclonal antibody (MoAb). J Clin Oncol; 2009 May 20;27(15_suppl):e16119

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of Id1 in human cancer has been related to poor prognosis breast, prostate (Gil-Bazo, Amer Soc Clin Oncol GU.
  • 2009) and other non-adenocarcinoma tumors.
  • CONCLUSIONS: For the first time using a MoAb against Id1 and in accord with our previous observations in prostate cancer the selection of PP pts increases tumor cell Id1 exp. from 28 up to 80%.
  • Id1 exp. profile in PP and metastatic initiation of BCa needs further research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gernone A, Pagliarulo V, Trabucco S: Prognostic role of somatostatin receptor subtypes in human prostate cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16120

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic role of somatostatin receptor subtypes in human prostate cancer.
  • : e16120 Background: Neuroendocrine differentiation (NED) in prostate carcinoma (PC) is frequently detected by immunohistochemistry as single cells in conventional adenocarcinoma.
  • METHODS: PC tissues were reviewed from 100 pts who had undergone biopsy or radical prostatectomy for previously untreated advanced or metastatic PC from 2002 to 2007.
  • The absence of SSTR 1 and 5 in more aggressive disease could represent a growth advantage in NED prostate cancer.
  • SSTRs and somatostatin analogs are potential targets for prostate cancer treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e20672 Background: Myelophthisis is a form of bone marrow failure due to replacement of hematopoietic tissue by abnormal tissue, most commonly metastatic carcinomas.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V: Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int; 2009;82(2):147-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma.
  • OBJECTIVES: We analyzed the incidence of elevated serum levels of chromogranin A (CgA) (as marker of neuroendocrine activity) in nonmetastatic and metastatic prostate cancer populations.
  • MATERIAL AND METHODS: 264 consecutive men with nonmetastatic prostate adenocarcinoma considered for radical prostatectomy (group 1) and 89 consecutive men with metastatic prostate adenocarcinoma (group 2) represented our population.
  • The OR for CgA level >60 and >90 ng/ml significantly increased from nonmetastatic to metastatic cases (p = 0.0001).
  • CONCLUSIONS: We describe a significant incidence of elevated serum levels of CgA either in nonmetastatic (using 60 ng/ml as cut-off) or in metastatic (using 90 ng/ml as cut-off) prostate adenocarcinoma cases.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Chromogranin A / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Odds Ratio. Prospective Studies. Prostate-Specific Antigen / blood. Risk Assessment. Up-Regulation

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19321999.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


17. Hung CF, Lee CH, Hung SW, Chiu KY, Cheng CL, Yang CR, Chen CJ, Li JR: Invasive adenocarcinoma of the prostate with urethral tumor. J Chin Med Assoc; 2010 Feb;73(2):101-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive adenocarcinoma of the prostate with urethral tumor.
  • Metastases of prostate cancer to the penis and urethra are rare and often represent advanced disease.
  • We describe a case of newly diagnosed prostatic adenocarcinoma with metastases to the corpus spongiosum, cavernosum, and the anterior urethra.
  • His prostate-specific antigen level was 5.02 ng/mL.
  • Digital rectal examination disclosed stony hard tumors at both lobes of the prostate.
  • Transrectal ultrasound-guided biopsy of the prostate revealed adenocarcinoma over both lobes; the Gleason score was 4 + 4 = 8.
  • Cystoscopy showed a penile urethral tumor and biopsy disclosed metastatic adenocarcinoma of the prostate; the Gleason score was 4 + 4 = 8.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Urethral Neoplasms / secondary
  • [MeSH-minor] Aged. Humans. Male. Prognosis. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20171591.001).
  • [ISSN] 1728-7731
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


18. Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, Eberhart CG, Clark DP, Bieberich CJ, Epstein JI, De Marzo AM: NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol; 2010 Aug;34(8):1097-105
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NKX3.1 as a marker of prostatic origin in metastatic tumors.
  • NKX3.1 is a prostatic tumor suppressor gene located on chromosome 8p.
  • Although most studies have shown that staining for NKX3.1 protein is positive in the majority of primary prostatic adenocarcinomas, it has been shown to be downregulated in many high-grade prostate cancers, and completely lost in the majority of metastatic prostate cancers (eg, in 65% to 78% of lesions).
  • A recent study showed that NKX3.1 staining with a novel antibody was highly sensitive and specific for high-grade prostatic adenocarcinoma when compared with high-grade urothelial carcinoma.
  • This raised the question that this antibody may perform better than earlier used antibodies in metastatic prostate tumors.
  • However, the sensitivity and specificity for prostate carcinomas for this antibody in metastatic lesions was not determined.
  • Although prostate-specific antigen (PSA) and prostatic-specific acid phosphatase (PSAP) are excellent tissue markers of prostate cancer, at times they may be expressed at low levels, focally, or not at all in poorly differentiated primary and metastatic prostatic adenocarcinomas.
  • The purpose of this study was to determine the performance of NKX3.1 as a marker of metastatic adenocarcinoma of prostatic origin.
  • Immunohistochemical staining against NKX3.1, PSA, and PSAP was carried out on a tissue microarray (TMA) (0.6-mm tissue cores) of hormone naïve metastatic prostate adenocarcinoma specimens from lymph nodes, bone, and soft tissue.
  • To determine the specificity of NKX3.1 for prostatic adenocarcinoma, we used TMAs that contained cancers from various sites including the urinary bladder, breast, colon, salivary gland, stomach, pancreas, thyroid, and central nervous system, and standard paraffin sections of cancers from other sites including the adrenal cortex, kidney, liver, lung, and testis.
  • The sensitivity for identifying metastatic prostatic adenocarcinomas overall was 98.6% (68/69 cases positive) for NKX3.1, 94.2% (65/69 cores positive) for PSA, and 98.6% (68/69 cores positive) for PSAP.
  • NKX3.1 seems to be a highly sensitive and specific tissue marker of metastatic prostatic adenocarcinoma.
  • In the appropriate clinical setting, the addition of IHC staining for NKX3.1, along with other prostate-restricted markers, may prove to be a valuable adjunct to definitively determine prostatic origin in poorly differentiated metastatic carcinomas.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Mar;163(3):972-9 [10688034.001]
  • [Cites] Arch Pathol Lab Med. 2008 Sep;132(9):1388-96 [18788849.001]
  • [Cites] Dev Dyn. 2000 Oct;219(2):248-60 [11002344.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6111-5 [11085535.001]
  • [Cites] J Urol. 2001 Apr;165(4):1329-34 [11257711.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1397-404 [11684956.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(5):1495-503 [11839815.001]
  • [Cites] Urology. 2001 Jun;57(6):1179-83 [11377343.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2884-9 [11854455.001]
  • [Cites] JAMA. 2002 Apr 3;287(13):1662-70 [11926890.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2220-6 [11956072.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):2999-3004 [12036903.001]
  • [Cites] Prostate. 2003 May 1;55(2):111-7 [12661036.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):3886-90 [12873978.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1607-14 [15111307.001]
  • [Cites] Mod Pathol. 2004 Mar;17(3):307-15 [14739905.001]
  • [Cites] Prostate. 2004 Aug 1;60(3):246-56 [15176054.001]
  • [Cites] J Urol. 2004 Sep;172(3):1134-9 [15311057.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):275-89 [15323145.001]
  • [Cites] Prostate. 2004 Nov 1;61(3):215-27 [15368473.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):3869-73 [7689419.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3273-7 [7515768.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jul;10(3):151-9 [7522037.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jul;13(3):168-74 [7669736.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2411-6 [8625320.001]
  • [Cites] Urology. 1997 Oct;50(4):643-7 [9338751.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4455-9 [9377551.001]
  • [Cites] Urology. 1998 Oct;52(4):637-40 [9763084.001]
  • [Cites] Clin Cancer Res. 1997 Jan;3(1):81-5 [9815541.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2259-69 [9840525.001]
  • [Cites] Genes Dev. 1999 Apr 15;13(8):966-77 [10215624.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1164-73 [15734999.001]
  • [Cites] Histopathology. 2005 Jul;47(1):1-16 [15982318.001]
  • [Cites] Ann N Y Acad Sci. 2005 Nov;1059:33-40 [16382041.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):88-104 [16512601.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10683-90 [17108105.001]
  • [Cites] Histopathology. 2007 Mar;50(4):472-83 [17448023.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1246-55 [17667550.001]
  • [Cites] Am J Surg Pathol. 2007 Sep;31(9):1351-5 [17721190.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1322-6 [18670358.001]
  • [Cites] Differentiation. 2008 Jul;76(6):717-27 [18557759.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • (PMID = 20588175.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058236-16; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / P50 CA058236-16; United States / NCI NIH HHS / CA / P50 CA058236-07; United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Homeodomain Proteins; 0 / NKX3-1 protein, human; 0 / Transcription Factors; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS272269; NLM/ PMC3072223
  •  go-up   go-down


19. Lath CO, Khanna PC, Gadewar S, Patkar DP: Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma. Australas Radiol; 2005 Dec;49(6):497-500
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastasis from prostatic adenocarcinoma simulating a meningioma.
  • We report an unusual case of extra-axial metastatic adenocarcinoma of the prostate that closely simulated a frontal, parasagittal, dural-based meningioma.
  • Such tumours, which satisfy several criteria for a diagnosis of meningioma, but which have proved instead to be metastatic adenocarcinoma of the prostate, form the focus of our report.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351616.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


20. Wright JL, Lin DW, Dewan P, Montgomery RB: Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer. Int J Urol; 2005 Nov;12(11):1012-3
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
  • We report a case of TLS in a patient with metastatic adenocarcinoma of the prostate after treatment with paclitaxel chemotherapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents, Phytogenic / adverse effects. Paclitaxel / adverse effects. Prostatic Neoplasms / therapy. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Bone Marrow Neoplasms / drug therapy. Bone Marrow Neoplasms / secondary. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Hematuria / etiology. Humans. Hydronephrosis / etiology. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Male. Middle Aged. Prostate-Specific Antigen / blood. Renal Dialysis. Renal Insufficiency / etiology. Renal Insufficiency / therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351664.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; EC 3.4.21.77 / Prostate-Specific Antigen; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Njiaju UO, Truica CI: Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report. Clin Breast Cancer; 2010 Feb;10(1):E3-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
  • Prostate adenocarcinoma can manifest as a fairly indolent tumor or as a very aggressive cancer with significant invasive and metastatic potential.
  • Common metastatic sites include bone, liver, lymph nodes, and adrenal glands.
  • We present a case of a man who presented with breast skin changes that mimicked inflammatory breast carcinoma with specialized testing ultimately giving a diagnosis of metastatic prostatic adenocarcinoma.
  • A skin biopsy showed metastatic carcinoma in dermal lymphatics, and the tumor was found to have no estrogen or progesterone receptors or HER2 expression.
  • Subsequent immunohistochemical staining on the tumor specimen was positive for prostate-specific antigen (PSA) and alpha-methyl-CoA-racemase, confirming a diagnosis of metastatic prostatic adenocarcinoma.
  • Prostatic adenocarcinoma presenting initially as a breast malignancy is a rarely recognizable clinical event.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms, Male / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Anilides / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Capecitabine. Carotid Stenosis / complications. Coronary Artery Disease / complications. Cyclophosphamide / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Diabetes Mellitus. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Leuprolide / administration & dosage. Male. Nitriles / administration & dosage. Osteoarthritis / complications. Positron-Emission Tomography. Prostate-Specific Antigen / analysis. Pulmonary Disease, Chronic Obstructive / complications. Tomography, X-Ray Computed. Tosyl Compounds / administration & dosage

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20133250.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen; EFY6W0M8TG / Leuprolide; U3P01618RT / Fluorouracil
  •  go-up   go-down


22. Bibbo C, Hatfield SP, Albright JT: Treatment of metastatic prostate adenocarcinoma to the calcaneus. J Foot Ankle Surg; 2010 Mar-Apr;49(2):159.e15-20
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic prostate adenocarcinoma to the calcaneus.
  • Metastatic skeletal adenocarcinoma is an all too common and unfortunate complication of advanced oncologic states.
  • The foot and ankle are uncommon sites for metastatic deposits, but may occur.
  • A team approach is mandatory to manage the patients with metastatic disease.
  • We present a case of an elderly male with a known history of prostate cancer, who presented with unrelenting heel pain, which upon diagnostic work-up, proved to be progressive calcaneal as well as axial metastasis after a brief period of clinical remission.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Bone Neoplasms / secondary. Bone Neoplasms / therapy. Calcaneus. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20015665.001).
  • [ISSN] 1542-2224
  • [Journal-full-title] The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons
  • [ISO-abbreviation] J Foot Ankle Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Adams G, Mitchell A, Ravichandran R, Beer TM, Garzotto M: Metastatic adenocarcinoma of prostate in a healing sternotomy site. Urology; 2006 Jul;68(1):204.e13-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of prostate in a healing sternotomy site.
  • Metastatic prostate cancer has a strong predilection for osseous sites, where the disease spreads in 80% of advanced cases.
  • The molecular mechanisms involved in prostate cancer establishment in bone are largely unknown; however, local tissue factors, including those involved in wound healing, have been suggested to play a critical role.
  • We present a case of tumor explosion in a median sternotomy wound after local prostate cancer therapy.
  • This case highlights that novel therapeutic interventions that disrupt the apparent synergistic relationship between tumor cells and the pro-tumorigenic microenvironment may hold great promise in constraining the proliferation of prostate cancer metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Prostatic Neoplasms / pathology. Sternum / surgery. Wound Healing

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808964.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kolias AG, Derham C, Mankad K, Hasegawa H, O'Kane R, Ismail A, Phillips NI: Multiple cranial neuropathy as the initial presentation of metastatic prostate adenocarcinoma: case report and review of literature. Acta Neurochir (Wien); 2010 Jul;152(7):1251-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cranial neuropathy as the initial presentation of metastatic prostate adenocarcinoma: case report and review of literature.
  • The skull base is an atypical metastatic site for prostate carcinoma.
  • However, skull base involvement causing cranial nerve palsies may rarely be the presenting sign of prostate carcinoma.
  • Here, we describe an unusual case of prostate adenocarcinoma presenting as a central skull base tumour with multiple cranial neuropathy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20379748.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


25. Zhang P, Zheng Y, Ran H, Leng Z, Wang Z: Case report: gastric adenocarcinoma metastatic to the prostate gland. J Radiol Case Rep; 2010;4(3):35-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: gastric adenocarcinoma metastatic to the prostate gland.
  • Metastasis to the prostate gland from gastric cancer is exceedingly rare.
  • We have presented a rare case of gastric malignancy metastasizing to the prostate diagnosed by transrectal ultrasound guided prostate biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470718.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303380
  • [Keywords] NOTNLM ; gastric adenocarcinoma / metastases / secondary prostatic cancer / transrectal ultrasound
  •  go-up   go-down


26. Chung SD, Yu HJ, Lin WC, Huang KH: Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level. J Formos Med Assoc; 2007 May;106(5):397-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostatic adenocarcinoma in an inguinal hernia sac in a patient with undetectable serum prostate specific antigen level.
  • Metastatic prostate cancer found within the hernia sac contents is a rare clinical manifestation.
  • We report a 64-year-old male patient who presented with rare clinical features of prostate cancer.
  • A focal metastasis of prostate cancer was incidentally found in an incised inguinal hernia sac 5 years after radical prostatectomy.
  • The serum prostate specific antigen (PSA) level remained undetectable (<0.01 ng/mL) prior to herniorrhaphy without any adjuvant therapy.
  • However, his serum PSA level started rising 12 months later and bladder invasion as well as a mass in the cul-de-sac was identified subsequently.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17561475.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


27. Kawahara T, Manabe Y, Asazuma A, Aoyama T, Hashimura T: [Hormone refractory prostate carcinoma metastasizes to the penis: a case report]. Hinyokika Kiyo; 2009 Oct;55(10):627-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hormone refractory prostate carcinoma metastasizes to the penis: a case report].
  • At 67-years-old, he was diagnosed with stage D2 prostate cancer and then, was treated with hormone therapy.
  • Several nodules were observed on the glans, and histological examination of the penile tumor biopsy showed metastatic adenocarcinoma of the prostate.
  • For the purpose of maintaining quality of life, transurethral resection of the prostate and partial penectomy were done.
  • [MeSH-major] Adenocarcinoma / pathology. Penile Neoplasms / secondary. Prostatic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19938335.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists
  •  go-up   go-down


28. Appetecchia M, Meçule A, Pasimeni G, Iannucci CV, De Carli P, Baldelli R, Barnabei A, Cigliana G, Sperduti I, Gallucci M: Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma. J Exp Clin Cancer Res; 2010;29:166
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma.
  • BACKGROUND: ChromograninA in prostate carcinoma (PC) indicate NE differentiation.
  • PATIENTS AND METHODS: We analyzed the incidence of pre-operative ChromograninA serum levels in non metastatic PC patients.
  • [MeSH-major] Adenocarcinoma / blood. Biomarkers, Tumor / blood. Chromogranin A / blood. Prostatic Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 2000 Mar 1;42(4):274-9 [10679756.001]
  • [Cites] Prostate. 2000 Mar 1;42(4):295-303 [10679759.001]
  • [Cites] J Urol. 2000 Apr;163(4):1161-4; discussion 1164-5 [10737487.001]
  • [Cites] Urology. 2000 Dec 20;56(6):1011-5 [11113749.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):7-15 [11391682.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S145-52 [11762343.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):512-5 [11792908.001]
  • [Cites] BJU Int. 2001 Nov;88(7):790-6 [11890255.001]
  • [Cites] Prostate. 2002 Oct 1;53(2):118-23 [12242726.001]
  • [Cites] Eur Urol. 2003 Aug;44(2):215-21 [12875941.001]
  • [Cites] Prostate. 2004 Mar 1;58(4):421-8 [14968443.001]
  • [Cites] Dig Liver Dis. 2004 Feb;36 Suppl 1:S60-7 [15077913.001]
  • [Cites] Eur Urol. 2004 May;45(5):586-92; discussion 592 [15082200.001]
  • [Cites] NCI Monogr. 1988;(7):15-8 [3173500.001]
  • [Cites] J Urol. 1991 Aug;146(2):358-61 [1856931.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3952-65 [7685237.001]
  • [Cites] J Urol. 1996 Apr;155(4):1340-3 [8632569.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1756-64 [8656243.001]
  • [Cites] J Urol. 1997 Feb;157(2):565-8 [8996358.001]
  • [Cites] Prostate. 1997 Jan 1;30(1):1-6 [9018329.001]
  • [Cites] Prostate. 1998 Feb 1;34(2):113-20 [9465942.001]
  • [Cites] Prostate Suppl. 1998;8:18-22 [9690659.001]
  • [Cites] Endocr Relat Cancer. 2005 Mar;12(1):109-17 [15788643.001]
  • [Cites] Arch Gerontol Geriatr. 2006 Jul-Aug;43(1):117-26 [16280180.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):229-34 [17177161.001]
  • [Cites] Prostate. 2007 May 1;67(6):645-52 [17342745.001]
  • [Cites] Eur Urol. 2007 Nov;52(5):1373 [17985422.001]
  • (PMID = 21162758.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC3018395
  •  go-up   go-down


29. Kabeer MA, Lloyd-Davies E, Maskell G, Hohle R, Mathew J: Metastatic prostate cancer masquerading clinically and radiologically as a primary caecal carcinoma. World J Surg Oncol; 2007;5:2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate cancer masquerading clinically and radiologically as a primary caecal carcinoma.
  • BACKGROUND: Prostatic carcinoma is the second most common cause of cancer-related deaths in males in the West.
  • Approximately 20% of patients present with metastatic disease.
  • We describe the case of a patient with metastatic prostate cancer to the bowel presenting clinically and radiologically as a primary caecal cancer.
  • The patient was being treated (Zoladex) for prostatic cancer diagnosed 6 years previously and was known to have bony metastases.
  • Histology showed a poorly differentiated adenocarcinoma which was PSA positive, confirming metastatic prostatic adenocarcinoma to the caecum.
  • CONCLUSION: Metastasis of prostatic carcinoma to the bowel is a very rare occurrence and presents a challenging diagnosis.
  • The treatment for metastatic prostate cancer is mainly palliative.
  • [MeSH-major] Adenocarcinoma / secondary. Cecal Neoplasms / secondary. Cecal Neoplasms / therapy. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2001 Jan;51(2):167-73 [11386414.001]
  • [Cites] Urology. 2001 Jul;58(1):106 [11445497.001]
  • [Cites] Arch Pathol Lab Med. 2001 Aug;125(8):1101-3 [11473469.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):61-4 [12004853.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1028-36 [12209687.001]
  • [Cites] Ann R Coll Surg Engl. 2003 Nov;85(6):382-5 [14629877.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):361-3 [15015669.001]
  • [Cites] Urology. 2004 Apr;63(4):778-9 [15072903.001]
  • [Cites] J R Soc Promot Health. 2004 Sep;124(5):219-21 [15493781.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1975 Dec;125(4):910-7 [1239960.001]
  • [Cites] Br J Neurosurg. 2000 Oct;14(5):473-4 [11198774.001]
  • [Cites] J Laryngol Otol. 1984 Aug;98(8):839-42 [6470579.001]
  • [Cites] Arch Otorhinolaryngol. 1985;241(3):219-24 [3896212.001]
  • [Cites] Cancer. 1986 Aug 15;58(4):985-93 [3719562.001]
  • [Cites] Neurosurgery. 1986 Nov;19(5):820-3 [3785633.001]
  • [Cites] J Surg Oncol. 1990 Mar;43(3):189-92 [2314106.001]
  • [Cites] Mo Med. 1991 Sep;88(9):642-4 [1745221.001]
  • [Cites] J Am Osteopath Assoc. 1991 Sep;91(9):895-7 [1757281.001]
  • [Cites] J Clin Gastroenterol. 1993 Mar;16(2):143-5 [8463618.001]
  • [Cites] Surg Today. 1993;23(7):632-4 [8369615.001]
  • [Cites] Head Neck. 1993 Sep-Oct;15(5):455-8 [8407319.001]
  • [Cites] Urology. 1995 Sep;46(3):406-7 [7544935.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):236-40 [9085174.001]
  • [Cites] J Ultrasound Med. 1997 Nov;16(11):751-3 [9360239.001]
  • [Cites] Tumori. 2004 Nov-Dec;90(6):535-46 [15762353.001]
  • [Cites] Arch Ital Urol Androl. 2005 Jun;77(2):109-10 [16146273.001]
  • [Cites] Urology. 2005 Oct;66(4):881 [16230172.001]
  • [Cites] J Clin Gastroenterol. 2001 May-Jun;32(5):439-40 [11319319.001]
  • [Cites] J Dermatol. 2006 Jan;33(1):46-51 [16469085.001]
  • [Cites] Mil Med. 2000 Dec;165(12):973-4 [11149072.001]
  • [Cites] Cancer. 1981 Sep 1;48(5):1262-4 [7272958.001]
  • (PMID = 17207288.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1779271
  • [General-notes] NLM/ Original DateCompleted: 20070802
  •  go-up   go-down


30. Castro Gómez JE, Anido Herranz U, Carballo Castro A, Gómez Caamaóo A, León Mateos LA, Porto Vázquez C, López López R: Brain metastases from prostate adenocarcinoma. Clin Transl Oncol; 2009 Jan;11(1):63-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases from prostate adenocarcinoma.
  • Brain metastases of prostate adenocarcinoma are rare.
  • We report a case of brain metastases from prostate adenocarcinoma 15 months after the diagnosis of the primary tumour.
  • The biopsy performed showed metastatic prostate adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155207.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Beer TM, Ryan C, Alumkal J, Ryan CW, Sun J, Eilers KM: A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Anticancer Drugs; 2010 Apr;21(4):433-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
  • Taxanes remain the only agents to extend survival in castration-resistant metastatic prostate cancer, but their impact on the natural history of this disease is modest.
  • Patients with metastatic adenocarcinoma of the prostate who progressed despite standard hormonal therapy and after docetaxel-containing chemotherapy were treated with transdermal estradiol (0.2 mg/24 h) for 4 weeks followed by the same dose of transdermal estradiol and paclitaxel poliglumex (PPX; 150 mg/m intravenous) every 28 days.
  • The primary objective was to determine the level of activity of the regimen measured using a fraction of patients who experienced a confirmed decline in serum prostate-specific antigen (PSA) of 50% or more.
  • In conclusion, this regimen of low-dose transdermal estradiol induction followed by PPX does not have activity in taxane pretreated patients with castration-resistant prostate cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Estradiol / therapeutic use. Paclitaxel / analogs & derivatives. Polyglutamic Acid / analogs & derivatives. Prostatic Neoplasms / drug therapy


32. Harik L, Nassar A: Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma. Arch Pathol Lab Med; 2006 Aug;130(8):1223-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal Rosai-Dorfman disease of the kidney and coexistent poorly differentiated prostatic adenocarcinoma.
  • We present a case of a patient who was initially diagnosed with poorly differentiated prostatic adenocarcinoma on prostate needle core biopsy.
  • Positron emission tomographic scan showed increased uptake in para-aortic, paracaval, and retrocaval lymph nodes suspicious for metastatic disease.
  • Lymphadenectomy revealed metastatic prostatic adenocarcinoma; however, the lymph nodes did not show evidence of Rosai-Dorfman disease.
  • The combination of prostatic adenocarcinoma and isolated extranodal Rosai-Dorfman disease of the kidney makes this case unique.
  • [MeSH-major] Adenocarcinoma / complications. Histiocytosis, Sinus / complications. Kidney Diseases / complications. Prostatic Neoplasms / complications

  • Genetic Alliance. consumer health - Kidney Disease.
  • Genetic Alliance. consumer health - Rosai-Dorfman disease.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879029.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Chacon G, Alexandraki I, Palacio C: Collet-sicard syndrome: an uncommon manifestation of metastatic prostate cancer. South Med J; 2006 Aug;99(8):898-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collet-sicard syndrome: an uncommon manifestation of metastatic prostate cancer.
  • Metastatic spread of prostate adenocarcinoma to the temporal bone is very rare.
  • A case of metastatic prostate adenocarcinoma involving the temporal bone causing Collet-Sicard syndrome is presented.
  • This case highlights an uncommon manifestation of prostate adenocarcinoma causing symptoms referable to the occipital condyle of the temporal bone.
  • Few cases have been reported in the literature of Collet-Sicard syndrome due to metastatic prostate cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Skull Neoplasms / secondary. Temporal Bone

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929891.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Lopez S, Simon JM, Mazeron JJ: [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate]. Bull Cancer; 2009 Mar;96(3):261-70
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
  • [Transliterated title] Hormono-radiothérapie des adénocarcinomes non métastatiques de la prostate.
  • Non-metastatic adenocarcinoma of prostate can be cured in the vast majority of cases with surgery and/or external or interstitial radiotherapy.
  • Analysis of results of recent randomised trials comparing this association and exclusive radiotherapy allows for validating concept of combined radiotherapy and hormone therapy in locally advanced adenocarcinoma of prostate, while many questions should be more clearly answered.
  • [MeSH-major] Androgen Antagonists / therapeutic use. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / radiotherapy. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Chemotherapy, Adjuvant. Combined Modality Therapy / methods. Gonadotropin-Releasing Hormone / analogs & derivatives. Humans. Male. Neoplasm Recurrence, Local / prevention & control. Prostate-Specific Antigen / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318304.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Androgen Antagonists; 33515-09-2 / Gonadotropin-Releasing Hormone; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 40
  •  go-up   go-down


35. Rapkiewicz A, Gorokhovsky R, Farcon E, Das K: Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge. Diagn Cytopathol; 2008 Jul;36(7):499-502
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytology of metastatic prostate cancer following orchiectomy and antiandrogen therapy: a diagnostic challenge.
  • Androgen deprivation therapy induces apoptosis and decreases both cell proliferation and angiogenesis in prostate adenocarcinoma.
  • The molecular alterations following androgen ablation translate into unique cytologic features in both primary and metastatic prostate adenocarcinoma.
  • We describe the cytologic appearance of metastatic prostate carcinoma following both surgical castration and androgen deprivation therapy.
  • [MeSH-major] Adenocarcinoma / pathology. Androgen Antagonists / therapeutic use. Biopsy, Fine-Needle. Orchiectomy. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Androgens / metabolism. Anilides / therapeutic use. Diagnosis, Differential. Histological Techniques. Humans. Male. Nitriles / therapeutic use. Prostate. Prostate-Specific Antigen / analysis. Tosyl Compounds / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18528888.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


36. Stanko C, Grandinetti L, Baldassano M, Mahmoodi M, Kantor GR: Epidermotropic metastatic prostate carcinoma presenting as an umbilical nodule-Sister Mary Joseph nodule. Am J Dermatopathol; 2007 Jun;29(3):290-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermotropic metastatic prostate carcinoma presenting as an umbilical nodule-Sister Mary Joseph nodule.
  • Carcinoma of the prostate accounts for fewer than 1% of all skin metastases.
  • Cutaneous metastases from prostate carcinoma most often involve the penis, the anterior aspect of the thighs, the suprapubic area, and the perineum, but they also have been reported in the scalp, the chest, the back, and even the face.
  • We report an unusual case of metastatic prostate adenocarcinoma that presented as an umbilical nodule (Sister Mary Joseph nodule) and demonstrated significant epidermotropism histologically.
  • A review of the literature has found only one documented case of prostatic carcinoma metastasizing to the umbilicus, and one other documented case of epidermotropic metastatic prostate carcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Skin Neoplasms / secondary. Umbilicus / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519629.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Amato RJ, Teh BS, Henary H, Khan M, Saxena S: A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Urol Oncol; 2009 Mar-Apr;27(2):165-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate.
  • OBJECTIVE: Chemotherapy for hormone-refractory prostate cancer reduces PSA levels and enhances overall survival (OS), suggesting that administration in earlier disease stages may be beneficial.
  • If expansion of an androgen-independent clone present during androgen deprivation mediates the transformation from an androgen-dependent to an androgen-independent phenotype, combination chemohormonal therapy would be effective initial treatment for locally advanced or metastatic prostate cancers.
  • MATERIALS AND METHODS: Chemohormonal therapy outcomes were retrospectively evaluated in men with locally advanced or metastatic prostate cancer seen at our institution between January 2001 and February 2003.
  • CONCLUSIONS: Combination chemohormonal therapy for locally advanced or metastatic prostate cancer safely and effectively reduces PSA levels and increases OS.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Humans. Male. Middle Aged. Neoplasm Metastasis. Phenotype. Prostate-Specific Antigen / metabolism. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367115.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


38. Frota AC, Bakalian S, Grégoire FJ, Fernandes BF, Burnier MN Jr: Pseudomelanoma in a patient with prostate adenocarcinoma. Can J Ophthalmol; 2007 Apr;42(2):305-6
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomelanoma in a patient with prostate adenocarcinoma.
  • CASE REPORT: A 72-year-old man referred for evaluation of a uveal melanoma was revealed with primary prostate adenocarcinoma metastatic to the choroid.
  • COMMENTS: Differential diagnosis of choroidal tumours may be difficult but should include both uveal melanoma and metastatic carcinoma to the uvea.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392857.001).
  • [ISSN] 0008-4182
  • [Journal-full-title] Canadian journal of ophthalmology. Journal canadien d'ophtalmologie
  • [ISO-abbreviation] Can. J. Ophthalmol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


39. Tsujino K, Sasada S, Kawahara K, Terada H, Komori C, Suzuki H, Okamoto N, Kobayashi M, Hirashima T, Matsui K, Kawase I: [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy]. Nihon Kokyuki Gakkai Zasshi; 2007 Aug;45(8):648-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of prostatic adenocarcinoma clinically presenting as supraclavicular and mediastinal lymphadenopathy].
  • We report a 70-year-old man with prostatic carcinoma presenting as supraclaviculer and mediastinal lymphadenopathy.
  • He had no urinary tract symptoms, and computed tomography and FDG-PET showed no abnormality in the prostate or pelvic lymph nodes.
  • Metastatic prostatic adenocarcinoma was finally diagnosed from the results of immunohistochemical staining for PSA of a biopsy specimen of the mediastinal lymph node, and he was treated by hormonal therapy.
  • Prostatic carcinoma should always be considered in the differential diagnosis of elderly men with supraclaviculer or mediastinal lymph node metastases, since appropriate treatment will lead to a prolonged survival.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymph Nodes / pathology. Lymphatic Diseases / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Lymphatic Metastasis. Male. Mediastinum. Prostate-Specific Antigen / blood

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17763696.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


40. Ahamed SH, Agarwal AK, Raju PP: Metastatic prostate carcinoma presenting as supraclavicular lymphadenopathy - is it unusual? Ann R Coll Surg Engl; 2006 Oct;88(6):W4-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate carcinoma presenting as supraclavicular lymphadenopathy - is it unusual?
  • Prostate carcinoma presenting initially as supraclavicular lymphadenopathy has been increasingly reported as an uncommon presentation of the disease.
  • The diagnosis is often made on lymph node biopsy as these patients rarely undergo digital rectal examination or serum prostate-specific antigen level measurement as part of their initial investigations.
  • The diagnosis of metastatic prostate adenocarcinoma was made only after cervical lymph node biopsy.
  • Following the diagnosis, he was confirmed as having an abnormal prostate on digital rectal examination and a raised serum prostate-specific antigen level.
  • The authors propose that a digital rectal examination and a serum prostate specific antigen level be included in the initial investigation process of male patients with persistent supraclavicular lymphadenopathy.
  • [MeSH-major] Adenocarcinoma / secondary. Jugular Veins. Lymphatic Diseases / pathology. Prostatic Neoplasms. Thrombosis / etiology
  • [MeSH-minor] Aged. Digital Rectal Examination. Humans. Male. Prostate-Specific Antigen / analysis

  • MedlinePlus Health Information. consumer health - Blood Clots.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1971 May;27(5):1055-63 [5581507.001]
  • [Cites] Am J Surg Pathol. 1987 Jun;11(6):457-63 [2438955.001]
  • [Cites] Br J Urol. 1984 Aug;56(4):385-90 [6534426.001]
  • (PMID = 17059705.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ PMC1963752
  •  go-up   go-down


41. Parwani AV, Marlow C, Demarzo AM, Mikolajczyk SD, Rittenhouse HG, Veltri RW, Chan TY: Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol; 2006 Oct;30(10):1231-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer.
  • Precursors of prostate-specific antigen (proPSA) have been previously shown to be more concentrated in prostate cancer tissue.
  • This study characterizes the immunohistochemical staining (IHS) of proPSA forms in metastatic prostate cancer compared with prostate specific antigen (PSA) and prostatic acid phosphatase (PAP).
  • A tissue microarray, consisting of 74 cases of metastatic prostate carcinoma and control tissues, was used.
  • The monoclonal antibodies were specific for both benign and malignant prostatic glandular tissue.
  • [-5/-7]pPSA (native proPSA) may be a better marker than PSA and PAP in characterizing metastatic prostate adenocarcinoma, with most of the cases showing positivity for the marker.
  • Such enhanced detection is particularly important in poorly differentiated carcinomas involving metastatic sites where prostate carcinoma is a consideration.
  • A panel of markers, including proPSA, should be performed when metastatic prostate carcinoma is in the differential diagnosis.
  • [MeSH-major] Adenocarcinoma / chemistry. Immunoenzyme Techniques / methods. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / chemistry. Protein Precursors / analysis. Protein Tyrosine Phosphatases / analysis

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001152.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Precursors; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Chiosea S, Jelezcova E, Chandran U, Acquafondata M, McHale T, Sobol RW, Dhir R: Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma. Am J Pathol; 2006 Nov;169(5):1812-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of dicer, a component of the MicroRNA machinery, in prostate adenocarcinoma.
  • In prostate adenocarcinoma, 39 microRNAs are up-regulated, and six microRNAs are down-regulated.
  • From a gene array analysis of 16 normal prostate tissue samples, 64 organ-confined, and four metastatic prostate adenocarcinomas, we identified an up-regulation of major components of the microRNA machinery, including Dicer, in metastatic prostate adenocarcinoma.
  • Immunohistochemical studies on a tissue microarray consisting of 232 prostate specimens confirmed up-regulation of Dicer in prostatic intraepithelial neoplasia and in 81% of prostate adenocarcinoma.
  • The increased Dicer level in prostate adenocarcinoma correlated with clinical stage, lymph node status, and Gleason score.
  • Western blot analysis of benign and neoplastic prostate cell lines further confirmed Dicer up-regulation in prostate adenocarcinoma.
  • Dicer up-regulation may explain an almost global increase of microRNA expression in prostate adenocarcinoma.
  • The presence of up-regulated microRNA machinery may predict the susceptibility of prostate adenocarcinoma to RNA interference-based therapy.
  • [MeSH-major] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. DEAD-box RNA Helicases / metabolism. Endoribonucleases / metabolism. MicroRNAs / metabolism. Prostatic Neoplasms / enzymology. Prostatic Neoplasms / pathology. Up-Regulation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Epithelium / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Microarray Analysis. Middle Aged. Prostate / cytology. Prostate / enzymology. Prostate / pathology. Ribonuclease III

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Cell Biol. 2004 Aug;6(8):784-91 [15247924.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):552-4 [14697225.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Genes Dev. 2003 Dec 15;17(24):3011-6 [14681208.001]
  • [Cites] Nat Neurosci. 2004 Feb;7(2):113-7 [14703574.001]
  • [Cites] Mol Biol Cell. 2004 Mar;15(3):1425-35 [14699070.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2790-9 [15254046.001]
  • [Cites] Eur Urol. 1996;30(2):201-5 [8875201.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 [9465086.001]
  • [Cites] Nat Cell Biol. 2004 Nov;6(11):1048-53 [15516998.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Cell. 2005 Jan 14;120(1):21-4 [15652478.001]
  • [Cites] Cancer Gene Ther. 2005 Mar;12(3):217-27 [15550938.001]
  • [Cites] Cancer Sci. 2005 Feb;96(2):111-5 [15723655.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):561-71 [15845026.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Curr Opin Struct Biol. 2005 Jun;15(3):331-41 [15925505.001]
  • [Cites] BMC Cancer. 2005;5:45 [15892885.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] J Exp Med. 2005 Jul 18;202(2):261-9 [16009718.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):740-4 [15973356.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Eur Urol. 2005 Nov;48(5):852-7 [16230228.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):688-93 [16271080.001]
  • [Cites] Cancer Gene Ther. 2005 Dec;12(12):926-34 [15956982.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] Curr Biol. 2005 Dec 6;15(23):2149-55 [16289642.001]
  • [Cites] Differentiation. 2005 Dec;73(9-10):463-73 [16351690.001]
  • [Cites] Genes Dev. 2005 Dec 15;19(24):2979-90 [16357216.001]
  • [Cites] Curr Opin Genet Dev. 2006 Feb;16(1):4-9 [16361094.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):179-86 [16432177.001]
  • [Cites] EMBO J. 2006 Feb 8;25(3):522-32 [16424907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Br J Cancer. 2006 Mar 27;94(6):776-80 [16495913.001]
  • [Cites] Genome Biol. 2006;7(3):210 [16584538.001]
  • [Cites] Science. 2002 Sep 20;297(5589):2056-60 [12154197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Cell. 2001 Jul 13;106(1):23-34 [11461699.001]
  • [Cites] Science. 2001 Aug 3;293(5531):834-8 [11452083.001]
  • [Cites] Prostate. 2002 May 1;51(2):98-107 [11948964.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jun;135(2):177-81 [12127403.001]
  • [Cites] Chin Med J (Engl). 2002 Apr;115(4):571-5 [12133301.001]
  • [Cites] Science. 2002 Sep 13;297(5588):1833-7 [12193640.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16648-53 [12482946.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):438-42 [12600936.001]
  • [Cites] Urology. 2003 Aug;62(2):378-84 [12893368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84 [12902540.001]
  • [Cites] EMBO J. 2004 Oct 13;23(20):4051-60 [15372072.001]
  • (PMID = 17071602.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; EC 3.1.- / Endoribonucleases; EC 3.1.26.3 / DICER1 protein, human; EC 3.1.26.3 / Ribonuclease III; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ PMC1780192
  •  go-up   go-down


43. Kumar A, Mukherjee SD: Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment. Can Urol Assoc J; 2010 Apr;4(2):E50-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal carcinoma of the prostate: a rare variant responding to a common treatment.
  • Ductal carcinoma of the prostate is a rare histologic subtype of prostate carcinoma.
  • It represents 0.4% to 0.8% of all prostate cancers and is associated with a poor prognosis.
  • Given the paucity of cases reported in the literature on ductal prostate carcinoma, little is known about how this cancer responds to cytotoxic chemotherapy.
  • We report the case of a 56-year-old male who presented to our clinic with hemoptysis, cough and hematuria and was found to have metastatic ductal carcinoma of the prostate.
  • He was initiated on docetaxel chemotherapy, which has been previously shown to improve overall survival in patients with metastatic prostate adenocarcinoma, but has never been studied in this less common subtype of prostate cancer.
  • To the best of our knowledge, the following is the first reported case of a patient with metastatic ductal carcinoma of the prostate responding to docetaxel chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2009 Jul 1;115(13):2872-80 [19402048.001]
  • [Cites] Urol Oncol. 2008 Jul-Aug;26(4):368-71 [18367098.001]
  • [Cites] Nat Clin Pract Urol. 2008 Jan;5(1):55-8 [18185514.001]
  • [Cites] Cancer. 2007 May 15;109(10):2011-5 [17420979.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):552-7 [11939729.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2118-24 [2004331.001]
  • [Cites] Am J Surg Pathol. 1985 Aug;9(8):595-609 [4091189.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] Cancer. 2002 May 15;94(10):2610-7 [12173328.001]
  • [Cites] Clin Adv Hematol Oncol. 2004 Jun;2(6):393-5; discussion 396 [16163211.001]
  • (PMID = 20368883.001).
  • [ISSN] 1920-1214
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2845672
  •  go-up   go-down


44. Hainsworth JD, Meluch AA, Spigel DR, Barton J Jr, Simons L, Meng C, Gould B, Greco FA: Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin Genitourin Cancer; 2007 Mar;5(4):278-83
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
  • BACKGROUND: Docetaxel is currently the standard first-line treatment in patients with hormone-refractory prostate cancer (HRPC).
  • Bortezomib, the first proteasome inhibitor in clinical use, demonstrated activity against prostate cancer in phase I trials.
  • All patients had metastatic adenocarcinoma of the prostate that had progressed on hormonal therapy.
  • Fifteen patients (25%; 95% confidence interval, 15%-38%) had a > 50% decrease in serum prostate-specific antigen level with treatment; the median response duration was 8 months.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Prostatic Neoplasms / drug therapy. Pyrazines / administration & dosage. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17553208.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 0 / Taxoids; 15H5577CQD / docetaxel; 69G8BD63PP / Bortezomib
  •  go-up   go-down


45. Alsuhaibani AH, Carter KD, Nerad JA, Lee AG: Prostate carcinoma metastasis to extraocular muscles. Ophthal Plast Reconstr Surg; 2008 May-Jun;24(3):233-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate carcinoma metastasis to extraocular muscles.
  • Prostate carcinoma, when metastatic, typically involves bone and produces both osteoblastic and osteolytic changes.
  • Orbital involvement is uncommon and extraocular muscle enlargement is a rare presentation of metastatic prostate adenocarcinoma.
  • The authors present 2 patients with prostatic tumor metastasis to extraocular muscles.
  • Clinicians should be aware that, although rare, prostate cancer can involve the extraocular muscles.
  • [MeSH-major] Adenocarcinoma / secondary. Eye Neoplasms / secondary. Muscle Neoplasms / secondary. Oculomotor Muscles / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520846.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Barbón JJ, González-Tuero J, Gay LL, Pérez-García FJ, Sampedro A: [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy]. Arch Soc Esp Oftalmol; 2007 Nov;82(11):715-7
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
  • [Transliterated title] Regresión de una metástasis coroidea de adenocarcinoma de próstata con tratamiento hormonal.
  • CASE REPORT: We report a case of a patient diagnosed with prostatic adenocarcinoma with multiple bone metastases and a choroidal metastasis in his left eye.
  • No metastatic recurrence has been demonstrated after a follow-up period of 14 months.
  • DISCUSSION: Complete resolution of choroidal metastases of prostatic adenocarcinoma with hormonal therapy is exceptional, but the effect of this treatment on such metastases should be observed before recommending radiation therapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Choroid Neoplasms / secondary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use
  • [MeSH-minor] Aged. Biopsy. Bone Neoplasms / secondary. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Prostate / pathology. Prostate-Specific Antigen / blood. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979041.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


47. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • BACKGROUND: Unique metastatic patterns cited in the literature often arise from anecdotal clinical observations and autopsy reports.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • METHODS: Tumor registry data were collected between 1994-1996 on 11 primary tumor sites and 15 metastatic sites from 4399 patients.
  • The primary and metastatic sites were cross-tabulated in various ways to identify patterns, and the authors developed algorithms by using multinomial logistic regression analysis to predict the locations of primary tumors based on metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • The liver was the dominant metastatic site for gastrointestinal (GI) primary tumors (71% of patients), whereas bone and lung metastases were noted most frequently in non-GI primary tumors (43% and 29%, respectively).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Rosa M, Chopra HK, Sahoo S: Fine needle aspiration biopsy diagnosis of metastatic prostate carcinoma to inguinal lymph node. Diagn Cytopathol; 2007 Sep;35(9):565-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy diagnosis of metastatic prostate carcinoma to inguinal lymph node.
  • Carcinoma of the prostate is predominantly a disease of older men.
  • Men younger than 50 years of age account for approximately 1% of all patients diagnosed with prostate cancer.
  • Patients generally present with urinary symptoms and rarely with metastatic disease.
  • We report a case of an aggressive prostate adenocarcinoma in a 47-year-old white male who presented with nausea, vomiting, and enlarged inguinal lymph nodes for 1 month.
  • A fine needle aspiration biopsy (FNAB) and immunohistochemical stains performed on the FNAB revealed metastatic prostatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Nodes / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17703448.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Adley BP, Maxwell K, Dalton DP, Yang XJ: Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma. Int Braz J Urol; 2006 Nov-Dec;32(6):681-7; discussion 687-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
  • Adenocarcinoma arising in urinary bladder or prostatic urethra is uncommon.
  • When they occur, the tumor can be mistaken for metastatic lesions, especially from the colon.
  • Here we report the fifth case of a primary urothelial-type adenocarcinoma arising in the prostate which showed enteric differentiation.
  • The patient was a 55 year-old male whose prostatic needle core biopsy showed a high grade adenocarcinoma which was initially thought to be metastatic colon cancer.
  • Subsequent prostatectomy revealed a high grade adenocarcinoma which was positive for cytokeratins 7 and 20, carcinoembryonic antigen, CDX2, and high molecular weight cytokeratin, and negative for prostate specific antigen, prostate specific acid phosphatase and AMACR.
  • A diagnosis of urothelial-type adenocarcinoma of the prostate was rendered.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201946.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


50. Llarena Ibarguren R, García-Olaverri Rodríguez J, Azurmendi Arin I, Olano Grasa I, Pertusa Peña C: [Metachronic testicular metastasis secondary to clear cell renal adenocarcinoma]. Arch Esp Urol; 2008 May;61(4):531-3
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metachronic testicular metastasis secondary to clear cell renal adenocarcinoma].
  • [Transliterated title] Metástasis testicular metacrónica secundaria a adenocarcinoma renal de células claras.
  • The pathology result was clear cell adenocarcinoma.
  • RESULTS: Six months later the patient continues under oral Sorafenib without evidence of new metastatic implants.
  • CONCLUSIONS: Testicular secondary metastatic tumors account for less than 1% of old testicular tumors.
  • In patients in the fifth and sixth decades, mainly if they are affected by other neoplasias, testicular masses use to be metastatic implants.
  • The most frequent origin is prostate.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592774.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


51. Haupt B, Ro JY, Ayala AG, Zhai J: Metastatic prostatic carcinoma to testis: histological features mimicking lymphoma. Int J Clin Exp Pathol; 2009;2(1):104-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostatic carcinoma to testis: histological features mimicking lymphoma.
  • We report a case of prostatic carcinoma with testicular metastasis, which mimicked malignant lymphoma of the testis.
  • The patient was a 71 year-old man with a history of prostate adenocarcinoma of Gleason score 9 (4+5) diagnosed in 2001 for which he received hormonal therapy.
  • However, immunohistochemical stains were positive for prostate-specific antigen and prostate acid phosphatase and negative for leukocyte common antigen, which confirmed the diagnosis of metastatic prostate adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Arch Esp Urol. 1994 Dec;47(10):992-7 [7864681.001]
  • [Cites] Ann Urol (Paris). 1994;28(5):274-6 [7825987.001]
  • [Cites] Br J Urol. 1993 May;71(5):600-6 [8518870.001]
  • [Cites] J Urol. 1989 Oct;142(4):1003-5 [2677407.001]
  • [Cites] Acta Radiol Oncol. 1984;23(4):239-47 [6093440.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):709-14 [6204734.001]
  • [Cites] Urology. 1984 Jun;23(6):598-9 [6730133.001]
  • [Cites] Histopathology. 1979 Jan;3(1):31-7 [428920.001]
  • [Cites] South Med J. 1971 Sep;64(9):1128-30 [5096298.001]
  • [Cites] Eur Urol. 2004 Apr;45(4):495-8 [15041115.001]
  • (PMID = 18830384.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; lymphoma / metastasis / prostate cancer / testis
  •  go-up   go-down


52. Chen CH, Tzai TS, Huang SP, Wu HC, Tai HC, Chang YH, Pu YS: Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups. Urology; 2008 Dec;72(6):1287-92
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of Taiwanese men with metastatic prostate cancer compared with other ethnic groups.
  • OBJECTIVES: Prostate cancer incidence varies significantly among different ethnic groups.
  • We sought to compare the survival outcome in patients with metastatic prostate cancer among different ethnic groups and to identify independent prognostic factors affecting overall survival in Taiwanese patients.
  • METHODS: From January 1996 to February 2005, 482 men with newly diagnosed metastatic prostate adenocarcinoma were enrolled from five major medical centers in Taiwan.
  • The cohort accounted for about 11.5% of all patients with metastatic disease during the period in Taiwan.
  • CONCLUSIONS: Taiwanese men with metastatic prostate cancer might have a better survival compared with Western men.
  • [MeSH-major] Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Ethnic Groups. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Prostate-Specific Antigen / biosynthesis. Retrospective Studies. Taiwan. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18372020.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


53. Shirakawa H, Kozakai N, Sugiura H, Hara S: [Urinary bladder metastasis of prostate cancer : a case report]. Hinyokika Kiyo; 2010 Feb;56(2):123-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urinary bladder metastasis of prostate cancer : a case report].
  • A 62-year-old man was referred to our outpatient clinic because of his elevated serum prostatic specific antigen level.
  • The transrectal ultrasonography guided biopsy of the prostate revealed prostate cancer.
  • Transurethral resection of the bladder tumor was performed, and histopathological examination showed the bladder tumor composed of not urothelial carcinoma but metastatic adenocarcinoma from prostate cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20186001.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Soulié M, Rozet F, Hennequin C, Salomon L, Membres du Sous-Comité Prostate du CCAFU: [Place of surgery in high-risk tumours of the prostate]. Cancer Radiother; 2010 Oct;14(6-7):493-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Place of surgery in high-risk tumours of the prostate].
  • [Transliterated title] Place de la chirurgie dans les tumeurs de la prostate à haut risque.
  • Among the different options recommended for high-risk prostate cancer, radical prostatectomy is admitted as radiotherapy, but its role is still controversial in monotherapy and difficult to evaluate in combined treatments.
  • The results of clinical trials combining an external radiotherapy to a long-term androgen deprivation in locally advanced tumours sustain the principle of a multidisciplinary management in high-risk prostate cancer.
  • Radical prostatectomy with an extended pelvic lymphadenectomy can be considered as a viable alternative to radiotherapy and hormonal therapy in these patients with a long life expectancy but presenting a high risk of local progression and a low risk of metastatic disease.
  • [MeSH-major] Adenocarcinoma / surgery. Prostatectomy. Prostatic Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20727805.001).
  • [ISSN] 1769-6658
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal
  •  go-up   go-down


55. Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, Song KH, Park JW: Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol; 2010 May;51(5):358-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen.
  • A 61-year-old man who had been diagnosed with prostate cancer 9 years ago and had been treated with pelvic irradiation and intermittent androgen deprivation therapy visited the emergency room because of back pain and weakness in both legs.
  • The serum prostate-specific antigen was 0.02 ng/ml.
  • He underwent laminectomy, posterior fixation, and epidural mass excision, and metastatic adenocarcinoma from the prostate was diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2007 Dec;12(6):427-32 [18071861.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):198-204 [17171704.001]
  • [Cites] J Urol. 1995 Dec;154(6):2128-31 [7500474.001]
  • [Cites] Urology. 2000 Sep 1;56(3):527-32 [10962338.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):374-9 [11442659.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):250-4 [10940696.001]
  • [Cites] Int Urol Nephrol. 2003;35(2):189-92 [15072491.001]
  • (PMID = 20495701.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2873892
  • [Keywords] NOTNLM ; Disease progression / Multiple organ failure / Neoplasm metastasis / Prostate-specific antigen / Prostatic neoplasms
  •  go-up   go-down


56. Lavasani L, Zapanta PE, Tanna N, Sadeghi N: Metastasis of prostatic adenocarcinoma to the sphenoid sinus. Ann Otol Rhinol Laryngol; 2006 Sep;115(9):690-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of prostatic adenocarcinoma to the sphenoid sinus.
  • The presentation, diagnosis, and management of prostatic adenocarcinoma metastatic to the sphenoid sinus are reviewed.
  • A 67-year-old man with a history of prostatic adenocarcinoma presented with gradual left visual loss.
  • Operative biopsy of the lesion was significant for adenocarcinoma of the prostate.
  • Furthermore, the pathophysiology and potential routes of metastatic disease should be assessed for these primary neoplasms.
  • Having a high level of suspicion for metastatic disease from specific primary sites will help guide the pathological evaluation.
  • As in this clinical scenario of a patient with a history of prostatic adenocarcinoma, appropriate analysis would entail sending specimens for immunohistochemical staining, such as prostate-specific antigen and prostate-specific acid phosphatase.
  • [MeSH-major] Adenocarcinoma / pathology. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology. Sphenoid Sinus / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044541.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Marlin ES, Hyams ES, Dulabon L, Shah O: Metastatic esophageal adenocarcinoma to the prostate presenting with bilateral ureteral obstruction. Can J Urol; 2010 Feb;17(1):5035-7
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic esophageal adenocarcinoma to the prostate presenting with bilateral ureteral obstruction.
  • Carcinoma metastatic to the prostate occurs rarely and is most commonly associated with malignant bladder neoplasms.
  • We present the case of a 73-year-old male with a history of gastroesophageal adenocarcinoma and clinically symptomatic benign prostatic hyperplasia who underwent photoselective vaporization of the prostate and presented several months later with gross hematuria, intermittent urinary retention and bilateral ureteral obstruction causing acute renal failure.
  • After relieving the ureteral obstruction, subsequent transurethral resection of the prostate revealed locally invasive metastatic esophageal adenocarcinoma.
  • To our knowledge, this is the first reported case of metastatic gastroesophageal carcinoma to the prostate.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Prostatic Neoplasms / secondary. Ureteral Obstruction / etiology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Neoplasm Invasiveness. Prostatic Hyperplasia / diagnosis. Prostatic Hyperplasia / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20156389.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


58. Mai KT, Roustan Delatour NL, Assiri A, Al-Maghrabi H: Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases. Diagn Cytopathol; 2007 Feb;35(2):91-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases.
  • Positive diagnosis of metastatic prostate adenocarcinoma (PAC) can be made by microscopic examination of the cytologic specimens and immunostaining for prostate-specific antigen (PSA) and prostate acid phosphatase (PAP).
  • The purpose of this study is to characterize the cytopathology of metastatic PAC as it has not been documented in large series.
  • Fifty cases of metastatic PAC with cytological specimens consisting of 41 fine-needle aspiration biopsies (FNAB), 6 pleural fluid aspirates, and 3 catheterized urine samples were reviewed and correlated with the surgical specimens and the clinical charts.
  • In addition to the frequency of high-grade PAC, awareness of the negative immunoreactivity to PSA and PAP, the discrepancy in the histopathological patterns between the primary and secondary tumors, especially the frequent neuroendocrine differentiation, are helpful features for the diagnosis of metastases of prostatic origin.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230567.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Llarena Ibarguren R, García-Olaverri Rodríguez J, Villafruela Mateos A, Azurmendi Arin I, Olano Grasa I, Pertusa Peña C: [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma]. Arch Esp Urol; 2007 Nov;60(9):1.137-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases in the paranasal sinuses secondary to prostatic adenocarcinoma].
  • [Transliterated title] Metástasis en senos paranasales secundaria a adenocarcinoma prostático.
  • OBJECTIVE: To report a new case of exceptional metastases from a prostatic carcinoma.
  • METHODS: 64-year-old male with nine months history of disseminated prostate cancer, taking hormonal treatment and biphosphonates, who presents with rising PSA, facial dysesthesia and left exophtalmos.
  • RESULTS: Once the diagnosis was established hormonal maneuvers were performed and chemotherapy with docetaxel was administered achieving at the start of treatment measurable disease stabilization with biochemical remission of PSA levels, followed posteriorly by progression without changes in the metastatic images.
  • CONCLUSIONS: 1% of the prostatic tumors involve the head in their evolution.
  • [MeSH-major] Adenocarcinoma / secondary. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077874.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


60. Zibzibadze M, Bochorishvili I, Ramishvili L, Managadze L, Kotrikadze N: Investigation of pro- and antioxidative systems' changes in blood of patients with prostate tumours. Georgian Med News; 2009 Apr;(169):26-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of pro- and antioxidative systems' changes in blood of patients with prostate tumours.
  • The aim of the study was to investigate changes in the content of primary, secondary and final LP products and quantitative changes of main antioxidant of plasma - Ceruloplsmin (Cp) in blood of patients with prostate tumors (benign prostate hyperplasia (BPH), benign prostate hyperplasia with PING(3-4) regions and metastatic prostate adenocarcinoma (PCa).
  • The tendency of diene conjugates reducing has been revealed compared with norm: The control group-->BPH-->benign prostate hyperplasia with PING(3-4)regions-->metastatic PCa.
  • MDA content was increased in all cases we had studied, but it was significantly increased in benign prostate hyperplasia with PING(3-4) regions and PCa.
  • Amount of Schiff's bases raised in lipid extracts in all cases of prostate cancer, especially in patients with benign prostate hyperplasia with PING(3-4) regions.
  • Strong intensification of LP in prostate cancer patients and accumulation of its final products occurs on the background of changes of the antioxidant system.
  • Both facts express disbalances of the anti- and prooxidative systems of organism in case of prostate gland malignant transformation.
  • [MeSH-major] Brain Neoplasms / blood. Lipid Peroxidation. Lipid Peroxides / blood. Prostatic Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19430038.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Lipid Peroxides; 4Y8F71G49Q / Malondialdehyde; EC 1.16.3.1 / Ceruloplasmin
  •  go-up   go-down


61. Pérez López ME, García Mata J, García Gómez J, Salgado Fernández M, Fírvida Pérez JL: [Prostate adenocarcinoma and synchcronous multiple myeloma: a case report]. Actas Urol Esp; 2007 Feb;31(2):157-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostate adenocarcinoma and synchcronous multiple myeloma: a case report].
  • [Transliterated title] Adenocarcinoma prostático y mieloma múltiple sincrónicos: a propósito de un caso.
  • PURPOSE: To report a case of synchronous prostatic cancer with multiple myeloma as inusual neoplasm presentation.
  • To indicate the clinical data that they help to suspect the myeloma presence in the prostate bone metastatic disease.
  • CASE REPORT: Patient 63 years old diagnosed of prostatic carcinoma with bone metastasis and BAC good responsive, who have clinical deterioration, hypercalcemia and renal insufficiency.
  • [MeSH-major] Adenocarcinoma / diagnosis. Multiple Myeloma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Prostatic Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645096.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Mhiri A, Hassad R, Sellem A, Bahri H, Diakite R, Slim I, Mahersi M, Hammami H, Ben Adallah M, Ben Slimene MF: [Treatment of painful bony metastases with Samarium 153-EDTMP in prostate carcinoma]. Tunis Med; 2007 Jul;85(7):580-5
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of painful bony metastases with Samarium 153-EDTMP in prostate carcinoma].
  • [Transliterated title] Traitement des metastases osseuses douloureuses par le Samarium 153-EDTMP dans le cancer de la prostate.
  • THE OBJECTIVE of this work is to evaluate a new therapy, the metabolic radiotherapy to the 153Samarium-EDTMP, of recent introduction in Tunisia, in the painful bony metastasis treatment observed at the patients affected of cancer of the prostate.
  • METHODS: It is about a retrospective survey with a receding of 40 months, achieved through 45 files of patients having benefited all of this new treatment for painful bony metastases in relation with a prostatic adenocarcinoma and collected by three centers of Nuclear Medicine of the capital: the institute Salah Azaiez (state-controlled), the Center CERU (deprives) and the Military hospital (HMPIT).
  • CONCLUSION: Its precocious introduction in the taken in charge of the metastatic patients, would allow them to benefit better from its efficiency, simplicity and weak toxicity and therefore to enjoy a better quality of life.
  • [MeSH-major] Analgesics, Non-Narcotic / therapeutic use. Bone Neoplasms / radiotherapy. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Pain, Intractable / radiotherapy. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064991.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Multicenter Study
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radioisotopes; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate
  •  go-up   go-down


63. Varghese S, Rabkin SD, Nielsen GP, MacGarvey U, Liu R, Martuza RL: Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res; 2007 Oct 1;67(19):9371-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
  • Here we show the efficacy of systemically administered oncolytic viruses for the treatment of spontaneously arising tumors, specifically the use of oncolytic herpes simplex viruses (HSV) administered i.v. to treat spontaneously developing primary and metastatic prostate cancer in the transgenic TRAMP mouse, which recapitulates human prostate cancer progression.
  • Four administrations of systemically delivered NV1023 virus, an HSV-1/HSV-2 oncolytic recombinant, to TRAMP mice at 12 or 18 weeks of age (presence of prostate adenocarcinoma or metastatic disease, respectively) inhibited primary tumor growth and metastases to lymph nodes.
  • Expression of interleukin 12 (IL-12) from NV1042 virus, a derivative of NV1023, was additionally effective, significantly reducing the frequency of development of prostate cancer and lung metastases, even when the mice were treated after the onset of metastasis at 18 weeks of age.
  • NV1042-infected cells, as detected by 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside staining for Lac Z expressed by the virus, were present in prostate tumors 1 week after the final virus injection and viral DNA was detected at 2 weeks after final virus injection by real-time PCR in primary and metastatic tumors but not in liver or blood.
  • The efficacy of the IL-12-expressing NV1042 virus in this aggressive prostate cancer model using a clinically relevant treatment paradigm merits its consideration for clinical studies.
  • [MeSH-major] Adenocarcinoma / therapy. Adenocarcinoma / virology. Oncolytic Virotherapy / methods. Prostatic Neoplasms / therapy. Prostatic Neoplasms / virology. Simplexvirus / physiology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909046.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA102139-0141; United States / NINDS NIH HHS / NS / P30 NS045776
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Thobe MN, Gurusamy D, Pathrose P, Waltz SE: The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells. Oncogene; 2010 Jan 14;29(2):214-26
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ron receptor tyrosine kinase positively regulates angiogenic chemokine production in prostate cancer cells.
  • However, no studies have examined Ron receptor expression or function during prostate tumorigenesis.
  • In this study we report that Ron is highly expressed in human prostate adenocarcinoma and metastatic lymph nodes when compared with normal prostate or benign prostate hyperplasia.
  • Furthermore, we show that Ron is overexpressed in PC-3 and DU145 prostate cancer cell lines, and that the levels of angiogenic chemokines produced by prostate cancer cells positively correlate with Ron expression.
  • Our data show that knockdown of Ron in prostate cancer cells results in significantly less endothelial cell chemotaxis when compared with Ron-expressing cells in vitro as well as in reduced tumor growth and decreased microvessel density after orthotopic transplantation into the prostate in vivo.
  • In total, our data suggest that the Ron receptor is important in modulating prostate tumor growth by modulating angiogenic chemokine production and subsequent endothelial cell recruitment.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2008 Dec;327(3):746-59 [18780829.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8504-10 [17875689.001]
  • [Cites] Shock. 2010 Feb;33(2):197-204 [19487969.001]
  • [Cites] FASEB J. 2000 Oct;14(13):2055-64 [11023990.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] Exp Cell Res. 2000 Nov 25;261(1):229-38 [11082293.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6142-51 [11593422.001]
  • [Cites] J Clin Endocrinol Metab. 2002 May;87(5):2376-83 [11994390.001]
  • [Cites] Oncogene. 2003 Jan 16;22(2):186-97 [12527888.001]
  • [Cites] Cancer Biother Radiopharm. 2003 Oct;18(5):829-40 [14629831.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Apr;286(4):C840-7 [14656722.001]
  • [Cites] Science. 1992 Dec 11;258(5089):1798-801 [1281554.001]
  • [Cites] Hepatology. 1993 Aug;18(2):394-9 [8340069.001]
  • [Cites] J Pathol. 2007 Dec;213(4):402-11 [17955509.001]
  • [Cites] Front Biosci. 2008;13:4595-604 [18508531.001]
  • [Cites] Adv Cancer Res. 2008;100:1-33 [18620091.001]
  • [Cites] Cell Tissue Res. 2008 Aug;333(2):237-52 [18523807.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1928-36 [18757292.001]
  • [Cites] Ann Oncol. 1994 Apr;5(4):305-11 [7521203.001]
  • [Cites] Am J Pathol. 1997 May;150(5):1571-82 [9137084.001]
  • [Cites] Blood. 1997 Aug 1;90(3):909-28 [9242519.001]
  • [Cites] Prostate. 1997 Sep 15;33(1):38-45 [9294625.001]
  • [Cites] Prostate. 1997 Oct 1;33(2):123-32 [9316653.001]
  • [Cites] J Clin Invest. 1998 Mar 1;101(5):1175-83 [9486989.001]
  • [Cites] Oncogene. 1998 Jun 4;16(22):2927-33 [9671413.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):783-9 [10213213.001]
  • [Cites] JAMA. 1999 May 5;281(17):1591-7 [10235151.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] FASEB J. 2005 Feb;19(2):243-5 [15548588.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1285-93 [15735014.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6190-7 [16144920.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6823-34 [16203770.001]
  • [Cites] Cancer Cell. 2005 Nov;8(5):393-406 [16286247.001]
  • [Cites] FASEB J. 2006 Jan;20(1):59-64 [16394268.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):768-78 [16510280.001]
  • [Cites] Urol Oncol. 2006 May-Jun;24(3):260-8 [16678061.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9162-70 [16982759.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11967-74 [17178895.001]
  • [Cites] Nat Genet. 2007 Jan;39(1):41-51 [17173048.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):967-75 [17283128.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3529-34 [17440059.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7570-5 [17456594.001]
  • [Cites] Cancer Res. 2007 Jul 1;67(13):6075-82 [17616662.001]
  • [Cites] Future Oncol. 2007 Aug;3(4):441-8 [17661719.001]
  • [Cites] Peptides. 2007 Sep;28(9):1896-901 [17544169.001]
  • [Cites] Plast Reconstr Surg. 2009 Feb;123(2 Suppl):65S-75S [19182665.001]
  • (PMID = 19838218.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA125370; United States / NCI NIH HHS / CA / R01 CA125379-02; United States / NCI NIH HHS / CA / CA-125370; United States / NCI NIH HHS / CA / R01 CA125379; United States / NCI NIH HHS / CA / CA125379-02; United States / NCI NIH HHS / CA / CA125379-01A2; United States / NCI NIH HHS / CA / R01 CA125379-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Chemokine CXCL1; 0 / Chemokine CXCL5; 0 / Chemokines; 0 / Interleukin-8; 0 / NF-kappa B; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ NIHMS145531; NLM/ PMC2806938
  •  go-up   go-down


65. Gong Y, Caraway N, Stewart J, Staerkel G: Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings. Am J Clin Pathol; 2006 Aug;126(2):302-9
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma of the prostate: cytologic features and clinical findings.
  • We retrospectively reviewed the cytologic features of metastatic prostatic ductal carcinoma (PDC) in 23 cases, clinical manifestations, and clinical outcomes.
  • A determination of a prostatic origin of a metastatic PDC, based on cytomorphologic features alone, could be difficult.
  • Immunostaining for prostate-specific antigen and prostatic acid phosphatase proved helpful in determining a definitive diagnosis.
  • [MeSH-major] Carcinoma, Ductal / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Biomarkers, Tumor / analysis. Biopsy, Needle. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16891207.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


66. Engehausen DG, Krause FS, Fleischmann J, Akcetin Z, Schrott KM, Endele S: Polymorphisms of human androgen receptor (hAR) gene in prostate cancer cell lines PC-EW and PC-OR. Anticancer Res; 2005 May-Jun;25(3A):1611-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of human androgen receptor (hAR) gene in prostate cancer cell lines PC-EW and PC-OR.
  • BACKGROUND: Prostate cancer is the leading tumor of the male in Western societies.
  • Genetic alterations of the androgen receptor gene are known in the advanced metastatic disease.
  • In this study, the androgen receptor gene was tested in two human prostate cancer cell lines, the androgen-sensitive PC-EW and the androgen-independent PC-OR.
  • MATERIALS AND METHODS: Genomic DNA was isolated from two cell lines from metastatic prostate adenocarcinoma in heterotransplanted male athymic nude (nu/nu) Balb/c mice.
  • CONCLUSION: Point mutations of hAR are not necessary for metastatic prostate cancer, while alterations in the solyglutamine and polyglycine repeat region in exon 1 of the MR gene are more often found.
  • These repeats are two of many genetic influences that contribute to the overall risk of developing prostate cancer.
  • [MeSH-major] Polymorphism, Genetic. Prostatic Neoplasms / genetics. Receptors, Androgen / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033069.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Receptors, Androgen
  •  go-up   go-down


67. Wu GJ, Fu P, Chiang CF, Huss WJ, Greenberg NM, Wu MW: Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model. J Urol; 2005 May;173(5):1778-83
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
  • PURPOSE: The transgenic adenocarcinoma mouse prostate (TRAMP) model is a paradigm that closely mimics the progression of clinical prostate cancer.
  • We have previously reported that MUC18, a cell adhesion molecule in the Ig gene superfamily, is a marker as well as an important mediator for the metastatic potential of human prostate cancer cells.
  • In this study we investigated the possible correlation of increased MUC18 expression with the malignant progression of prostate cancer in the TRAMP model.
  • MATERIALS AND METHODS: We used immunohistochemistry, Western blot and reverse transcriptase-polymerase chain reaction analyses to determine MUC18 expression in the prostate gland of 178 to 282-day-old TRAMP positive males with a prostate tumor size of 0.4 to 12.7 gm.
  • Eight normal prostates, 10 prostates with high grade prostatic intraepithelial neoplasia (PIN), 24 prostates with primary prostate cancer, 10 metastatic lesions from 50 pure C57BL/6 TRAMP mice (Wu colony) and 2 normal prostates, 2 prostates with high grade PIN, 6 prostates with primary prostate cancer and 4 metastatic lesions from 10 [C57BL/6 TRAMP x FVB] F1 mice (NMG colony) were used.
  • RESULTS: We found that mouse MUC18 was expressed in all (100%) high grade PIN, adenocarcinomas and metastatic lesions.
  • All mice bearing primary prostate tumors had prostate cancer metastatic to the peri-aortic lymph nodes and some had it to other organs (liver, lung, kidney, testes, seminal vesicles and abdominal cavity).
  • CONCLUSIONS: MUC18 expression is up-regulated in the TRAMP model and it correlates with the malignant progression of mouse prostate adenocarcinoma in this transgenic model.
  • This further strengthens the hypothesis that MUC18 has an important role in increasing the metastatic potential of prostate cancer cells.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antigens, CD / biosynthesis. Biomarkers, Tumor / biosynthesis. Neural Cell Adhesion Molecules / biosynthesis. Prostatic Neoplasms / metabolism. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15821586.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD146; 0 / Biomarkers, Tumor; 0 / Mcam protein, mouse; 0 / Neural Cell Adhesion Molecules
  •  go-up   go-down


68. Kattan JG, Farhat FS, Chahine GY, Nasr FL, Moukadem WT, Younes FC, Yazbeck NJ, Ghosn MG, Cancer Research Group: Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest New Drugs; 2008 Feb;26(1):75-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
  • Treatment options for patients with hormone refractory prostate cancer (HRPC) showed unsatisfactory outcomes.
  • Eligibility consisted of metastatic prostate adenocarcinoma with objective progression or rising prostate specific antigen levels (PSA) despite androgen deprivation therapy.
  • Three (21%) patients among the 14 with measurable disease had objective response: 1 complete response (CR) and 2 partial responses (PR).
  • Response duration was 2 months for PR and 4 months for CR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Administration, Oral. Aged. Aged, 80 and over. Alopecia / chemically induced. Anemia / chemically induced. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Diphosphonates / administration & dosage. Diphosphonates / adverse effects. Drug Administration Schedule. Estramustine / administration & dosage. Estramustine / adverse effects. Fatigue / chemically induced. Humans. Hypocalcemia / chemically induced. Imidazoles / administration & dosage. Imidazoles / adverse effects. Infusions, Intravenous. Injections, Intravenous. Male. Middle Aged. Prostate-Specific Antigen / blood. Taxoids / administration & dosage. Taxoids / adverse effects. Thrombocytopenia / chemically induced. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846704.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 0 / Taxoids; 15H5577CQD / docetaxel; 35LT29625A / Estramustine; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


69. Khandani AH, Funkhouser WK, Feins R, Socinski MA: Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer. Ann Nucl Med; 2009 Aug;23(6):595-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous FDG PET+/Glut1+ lung and FDG PET-/Glut1- subcarinal lymph node metastases from prostate cancer.
  • A 78-year-old man with a history of prostate cancer and a rise in PSA presented with a new left lung mass, detected on computed tomography (CT).
  • Surgical resection of the mass and mediastinal lymph node dissection revealed metastatic adenocarcinoma from prostate cancer in the left lung mass (tumor size 5 cm) as well as in a subcarinal lymph node (tumor size 1.9 cm), which were identical on hematoxylin and eosin stains with a Gleason score of 8.
  • [MeSH-major] Fluorodeoxyglucose F18. Glucose Transporter Type 1 / metabolism. Lung Neoplasms / radionuclide imaging. Lung Neoplasms / secondary. Prostatic Neoplasms / pathology


70. Kessler T, Wissenbach U, Grobholz R, Flockerzi V: TRPV6 alleles do not influence prostate cancer progression. BMC Cancer; 2009;9:380
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPV6 alleles do not influence prostate cancer progression.
  • Several studies have shown that TRPV6 transcripts are expressed in locally advanced prostatic adenocarcinoma, metastatic and androgen-insensitive prostatic lesions but are undetectable in healthy prostate tissue and benign prostatic hyperplasia.
  • We now asked, whether the trpv6a allele is correlated with the onset of prostate cancer, with the Gleason score and the tumour stage.
  • METHODS: Genomic DNA of prostate cancer patients and control individuals was isolated from resections of prostatic adenocarcinomas and salivary fluid respectively.
  • RNA used for RT-PCR was isolated from prostate tissue.
  • The incidence of prostate cancer is several times higher in African populations than in non-African and we then investigated the TRPV6a/b frequencies in 141 samples of prostatic adenocarcinoma.
  • CONCLUSION: Our results show that the frequencies of trpv6 alleles in healthy control individuals and prostate cancer patients are not significantly different.
  • Although expression of trpv6 transcripts correlates with aggressive potential of prostate cancer, the TRPV6 genotype does not correlate with the onset of prostate cancer, with the Gleason score and the tumour stage.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Calcium Channels / genetics. Prostatic Neoplasms / genetics. Prostatic Neoplasms / pathology. TRPV Cation Channels / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 18;275(1):47-52 [10944439.001]
  • [Cites] PLoS One. 2008;3(2):e1686 [18301763.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3760-9 [11325849.001]
  • [Cites] J Biol Chem. 2001 Jun 1;276(22):19461-8 [11278579.001]
  • [Cites] Lab Invest. 2002 Dec;82(12):1755-64 [12480925.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7858-61 [14586412.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3691-7 [14666665.001]
  • [Cites] Urology. 2003 Dec 22;62(6 Suppl 1):3-12 [14706503.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Oct 1;322(4):1359-63 [15336984.001]
  • [Cites] Glia. 2004 Nov 1;48(2):112-9 [15378657.001]
  • [Cites] PLoS Biol. 2004 Oct;2(10):e286 [15361935.001]
  • [Cites] Henry Ford Hosp Med J. 1992;40(1-2):89-92 [1428986.001]
  • [Cites] Am J Clin Pathol. 1994 Nov;102(5):572-9 [7942619.001]
  • [Cites] Urology. 1994 Nov;44(5):637-45 [7526522.001]
  • [Cites] Annu Rev Public Health. 1995;16:283-306 [7543756.001]
  • [Cites] Genomics. 1996 Jul 1;35(1):207-14 [8661122.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Oncology (Williston Park). 1997 May;11(5):599-605; discussion 606-15 passim [9159788.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(4):213-8 [9315393.001]
  • [Cites] J Biol Chem. 1999 Aug 6;274(32):22739-46 [10428857.001]
  • [Cites] Mol Biol Evol. 2005 Jan;22(1):63-73 [15356276.001]
  • [Cites] Am J Surg Pathol. 2005 Sep;29(9):1228-42 [16096414.001]
  • [Cites] Genome Res. 2005 Nov;15(11):1592-3 [16251469.001]
  • [Cites] Cell Calcium. 2006 Feb;39(2):163-73 [16356545.001]
  • [Cites] Virchows Arch. 2006 Feb;448(2):111-8 [16328356.001]
  • [Cites] Hum Mol Genet. 2006 Jul 1;15(13):2106-13 [16717058.001]
  • [Cites] Lancet Oncol. 2007 May;8(5):411-9 [17466898.001]
  • [Cites] Am J Pathol. 2000 Nov;157(5):1549-62 [11073814.001]
  • (PMID = 19857260.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium Channels; 0 / TRPV Cation Channels; 0 / TRPV6 protein, human
  • [Other-IDs] NLM/ PMC2774862
  •  go-up   go-down


71. Moura FM, Garcia LT, Castro LP, Ferrari TC: Prostate adenocarcinoma manifesting as generalized lymphadenopathy. Urol Oncol; 2006 May-Jun;24(3):216-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate adenocarcinoma manifesting as generalized lymphadenopathy.
  • Generalized lymphadenopathy is a rare manifestation of metastatic prostate cancer.
  • There were no urinary symptoms, and the serum prostate-specific antigen (PSA) was only mildly increased with a normal free PSA.
  • A biopsy of the supraclavicular lymph node was compatible with adenocarcinoma, whose prostatic origin was shown by immunohistochemical staining with PSA.
  • The origin of the primary tumor was confirmed by directed prostate biopsy.
  • We emphasize that a suspicion of prostate cancer in men with adenocarcinoma of undetermined origin is important for an adequate diagnostic and therapeutic approach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lymphatic Diseases / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Prostate-Specific Antigen / analysis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678051.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


72. Bergner CC, Krause FS, Zugor V, Rith T, Schrott KM, Endele S, Engehausen DG: Polymorphisms of human estrogen receptor (ER) gene alpha and beta in prostate cancer PC-EW and PC-OR cell lines. Anticancer Res; 2007 Jul-Aug;27(4A):2071-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of human estrogen receptor (ER) gene alpha and beta in prostate cancer PC-EW and PC-OR cell lines.
  • BACKGROUND: Prostate cancer is the second leading cause of death among men in Western countries.
  • In this study the estrogen receptor alpha and beta genes were tested in 2 human prostate cancer cell lines: the hormone-sensitive PC-EW and the hormone-independent PC-OR.
  • MATERIALS AND METHODS: Genomic DNA was isolated from 2 cell lines from metastatic prostate adenocarcinoma in hetero-transplanted male athymic nude (nu/nu) Balb/c mice.
  • CONCLUSION: Point mutations of ER-alpha and -beta are not necessary for metastatic prostate cancer, alterations in different areas of the ER genes are more often found.
  • These polymorphisms are a part of many genetic influences that accumulate to contribute to men's overall risk for developing prostate cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Genetic Predisposition to Disease. Polymorphism, Single Nucleotide. Prostatic Neoplasms / genetics

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649823.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta
  •  go-up   go-down


73. Petraki CD, Sfikas CP: Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol Histopathol; 2007 01;22(1):107-18
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma.
  • The effect of androgen deprivation and other hormonal therapies, radiation therapy, thermal ablation therapies, chemotherapy, and other systemic treatments is evident in the histology of non-neoplastic and neoplastic human prostate gland.
  • Androgen deprivation therapies cause atrophy of non-neoplastic and neoplastic prostatic epithelium, as the result of apoptosis, and are mainly used as a palliative measure in metastatic prostate cancer or as neoadjuvant or adjuvant treatment, in clinically localized prostate cancer.
  • Radiation therapy may be applied in the form of external beam, interstitial implantation (brachytherapy), or a combination, as a mainstay or adjuvant (external beam) treatment in localized prostate cancer.
  • The difficulty of post-radiation prostate needle biopsy interpretation includes the distinction of treatment effect in normal prostatic tissue from recurrent or residual tumour.
  • Histological changes after thermal ablation mainly include lesions observed in prostatic infarcts due to periurethral coagulative type necrosis of variable volume.
  • [MeSH-major] Adenocarcinoma / therapy. Prostate / drug effects. Prostate / pathology. Prostate / radiation effects. Prostatic Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17128417.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Androgens; 0 / Antineoplastic Agents; 0 / Estrogens; EC 1.3.1.22 / Cholestenone 5 alpha-Reductase
  • [Number-of-references] 95
  •  go-up   go-down


74. Kalender ME, Sevinc A, Kucukdurmaz Z, Balik A, Sari I, Camci C: Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor. Onkologie; 2007 Nov;30(11):568-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor.
  • Prostate cancer is the most common non-cutaneous cancer.
  • The most frequently encountered second malignancies in patients with prostate adenocarcinoma include carcinomas of the bladder, stomach, and colon, followed by cutaneous and hematolymphoid malignancies.
  • 2 years later, the patient was diagnosed with gastric adenocarcinoma, and a subtotal gastrectomy and gastrojejunostomy were performed.
  • At followup 6 months later, prostate-specific antigen (PSA) levels were elevated, and a prostate biopsy showed a prostate adenocarcinoma.
  • CONCLUSION: This is the second report of metachronous prostate cancer, gastric cancer, and GIST in the English language literature.
  • [MeSH-major] Gastrointestinal Stromal Tumors / diagnosis. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / secondary. Stomach Neoplasms / diagnosis. Stomach Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992028.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


75. Patel V, Castell FA, Akinwunmi J, Francis I, Chandrasekharan L, Malhotra R: Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion. Orbit; 2010 Aug;29(4):213-5
MedlinePlus Health Information. consumer health - Prostate Cancer Screening.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostatic adenocarcinoma presenting with metastatic frontal bone involvement and orbital invasion.
  • We present a rare case of prostatic adenocarcinoma presenting with metastatic frontal bone involvement with subsequent spread to the orbit.
  • Although prostatic adenocarcinoma has a strong tendency to metastasize to bone, particularly axial skeletal bone, frontal bone involvement is rare and subsequent orbital involvement is even more so.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Invasiveness / pathology. Orbital Neoplasms / secondary. Orbital Neoplasms / surgery. Prostate-Specific Antigen / blood. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20812840.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


76. Molenaar JP, Baten A, Blokx WA, Hoogendam A: Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate. Eur Urol; 2009 Nov;56(5):874-7; quiz 876
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of carcinoid tumour in hormonally treated adenocarcinoma of the prostate.
  • We present the case of an 81-yr-old man with a prostatic adenocarcinoma and a metastatic carcinoid.
  • Simultaneous occurrence of hormonally treated adenocarcinoma of the prostate and a carcinoid has been described before.
  • The pathogenesis of this coincidence is largely unclear; however, androgen deprivation therapy might play a key role in neuroendocrine differentiation of adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Carcinoid Tumor / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary. Nitriles / therapeutic use. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19171417.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 51110-01-1 / Somatostatin; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


77. Boyiadzis M, Nam M, Dahut W: Fulminant hepatic failure secondary to metastatic prostate cancer. Urol Int; 2005;74(2):185-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatic failure secondary to metastatic prostate cancer.
  • The most common sites of metastatic disease from prostate cancer include the bones, lymph nodes and less commonly the lungs, adrenal glands, brain and kidneys.
  • We describe a case of fatal liver failure in a 71-year-old male due to metastases to the liver from a prostatic adenocarcinoma.
  • Thus in patients with metastatic cancer and elevated liver function tests, the possibility of hepatic involvement by the cancer should be considered as a possible cause of hepatic failure.
  • [MeSH-major] Adenocarcinoma / complications. Liver Failure, Acute / etiology. Liver Neoplasms / complications. Prostatic Neoplasms / pathology


78. Herawi M, De Marzo AM, Kristiansen G, Epstein JI: Expression of CDX2 in benign tissue and adenocarcinoma of the prostate. Hum Pathol; 2007 Jan;38(1):72-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
  • Numerous studies have claimed that CDX2 is relatively specific and sensitive in establishing a gastrointestinal origin in metastatic tumors of unknown origin.
  • We have recently seen 2 cases of prostatic adenocarcinoma (PCa) on needle biopsies with diffuse strong nuclear staining for CDX2 sent for consultation.
  • One case was a prostatic duct adenocarcinoma in a man with a prostate-specific antigen (PSA) value of 327 ng/mL, and the other was a PCa with a Gleason score (GS) of 4 + 4 = 8 in a man with a PSA value of 15 ng/mL.
  • An adenocarcinoma with GS 3 + 3 = 6 from the contralateral side did not express CDX2.
  • Three slides of TMAs were used to stain 708 tissue samples (0.6 mm in diameter) containing either benign or malignant prostate tissue, as well as control tissues from various anatomical sites including colon.
  • In total, 195 samples of primary PCa with GS of 6 (n = 41), 7 (n = 21), and 8 (n = 8); 195 samples of benign prostate tissue; and 185 samples of metastatic PCa were studied.
  • Focal moderate positive staining was seen in benign prostate tissue in 7 (11.7%) of 60 radical prostatectomy specimens.
  • None of the metastatic PCa expressed CDX2.
  • CDX2 may uncommonly be focally expressed in benign prostatic glands.
  • Positive CDX2 staining in high-grade prostate cancer (ductal, cribriform, and solid) may be confused with secondary carcinoma of colonic origin.
  • [MeSH-major] Adenocarcinoma / pathology. Homeodomain Proteins / biosynthesis. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Immunohistochemistry. Male. Middle Aged. Prostate-Specific Antigen / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16949907.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA58236
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / Homeodomain Proteins; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


79. Kundranda MN, Muslimani A, Daw HA, Spiro TP: Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Clin Genitourin Cancer; 2007 Sep;5(6):401-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.
  • An 83-year-old man was diagnosed with stage 4 prostate cancer with a Gleason score of 7 (3+4).
  • His initial prostate-specific antigen (PSA) level was 965 ng/dL, and he demonstrated extensive metastatic disease of the thoracic spine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / administration & dosage. Anilides / administration & dosage. Nitriles / administration & dosage. Prostatic Neoplasms / drug therapy. Tosyl Compounds / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Male. Prostate-Specific Antigen / blood. Remission Induction. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956714.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


80. Hematpour K, Bennett CJ, Rogers D, Head CS: Supraclavicular lymph node: incidence of unsuspected metastatic prostate cancer. Eur Arch Otorhinolaryngol; 2006 Sep;263(9):872-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Supraclavicular lymph node: incidence of unsuspected metastatic prostate cancer.
  • An uncommon presentation of prostate carcinoma to the supraclavicular lymph nodes is herein reviewed.
  • The clinical features of four cases involving metastatic prostate carcinoma will be discussed.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1986 Dec;96(12):1352-6 [3784739.001]
  • [Cites] Laryngoscope. 1973 Sep;83(9):1527-39 [4758761.001]
  • [Cites] Cancer. 1954 Nov;7(6):1246-8 [13209524.001]
  • [Cites] JAMA. 1993 Aug 25;270(8):948-54 [7688438.001]
  • [Cites] Cancer. 1984 Dec 15;54(12):3078-84 [6498785.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • (PMID = 16830117.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


81. Kitley CA, Mosier AD, Keylock J, Nguyen D: Malignant priapism secondary to adenocarcinoma of the prostate. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant priapism secondary to adenocarcinoma of the prostate.
  • The authors report a case of an older gentleman with a history of metastatic prostate cancer who presented to the emergency department following 3 weeks of progressively intermittent and then continuous priapism.
  • After an initial clinical workup, an MRI was performed of the pelvis for further evaluation of the patient's condition which demonstrated metastatic lesions within his corpora cavernosa.
  • [MeSH-major] Adenocarcinoma / diagnosis. Penile Neoplasms / secondary. Priapism / etiology. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy, Large-Core Needle. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Diagnosis, Differential. Disease Progression. Fatal Outcome. Follow-Up Studies. Humans. Image Interpretation, Computer-Assisted. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Palliative Care. Penis / pathology. Prostate / pathology. Tomography, X-Ray Computed. Urinary Bladder / pathology

  • Genetic Alliance. consumer health - Priapism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 2001 Oct;21 Spec No:S283-98; discussion S298-9 [11598264.001]
  • [Cites] J Androl. 2003 Jul-Aug;24(4):499-500 [12826689.001]
  • [Cites] Radiol Clin North Am. 2004 Mar;42(2):427-43 [15136026.001]
  • [Cites] Eur Urol. 1987;13(5):351-2 [3315692.001]
  • [Cites] Urol Int. 1994;52(1):52-4 [8140683.001]
  • [Cites] Urology. 1998 Feb;51(2):324-6 [9495721.001]
  • [Cites] J Surg Oncol. 1998 May;68(1):51-9 [9610664.001]
  • [Cites] Urol Clin North Am. 2007 Nov;34(4):631-42, viii [17983902.001]
  • (PMID = 22789733.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3028547
  •  go-up   go-down


82. Yeh IT, Reddick RL, Kumar AP: Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate; 2009 May 15;69(7):755-60
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
  • BACKGROUND: Transgenic adenocarcinoma of mouse prostate (TRAMP) mice, derived by prostate specific expression of SV40 large T antigen using the rat probasin promoter, all develop prostate tumors akin to human prostate cancers.
  • Immunostains (cytokeratin, vimentin, desmin, and MIB-1) and electron microscopy were performed on selected blocks of the genitourinary system and metastatic tumor nodules.
  • In some cases, the stromal cells become large mass lesions that overgrow the prostate.
  • Some metastatic tumors have characteristics similar to the seminal vesicle ES tumor.
  • CONCLUSIONS: Metastatic tumors in TRAMP mice show three patterns:.
  • (1) A definite adenocarcinoma pattern metastatic from the prostate;.
  • [MeSH-major] Adenocarcinoma / pathology. Prostatic Neoplasms / pathology. Seminal Vesicles / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19170049.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Osunkoya AO, Epstein JI: Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases. Am J Surg Pathol; 2007 Sep;31(9):1323-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucin-producing urothelial-type adenocarcinoma of prostate: report of 15 cases.
  • Prostatic urothelial-type adenocarcinoma arises through a process of glandular metaplasia of the prostatic urethral urothelium and subsequent in situ adenocarcinoma sometimes associated with villous adenoma.
  • These prostatic adenocarcinomas are analogous to nonurachal adenocarcinomas arising in the bladder from cystitis glandularis.
  • Only 2 cases of urothelial-type adenocarcinoma from an institution other than our own have been previously described.
  • The distinction between adenocarcinoma from another organ secondarily involving the prostate, usual adenocarcinoma of the prostate, and prostatic urothelial-type adenocarcinoma can present a significant diagnostic challenge and has significant therapeutic implications.
  • Fifteen cases of prostatic urothelial-type adenocarcinoma were retrieved from the consult files of one of the authors.
  • Four men (26.7%) developed metastatic disease and 8 (53.3%) died of disease.
  • In 8/15 (53%) cases, glandular metaplasia of the prostatic urethra and contiguous transition to adenocarcinoma were identified.
  • Immunohistochemical stains were negative for prostate specific antigen, prostate specific acid phosphatase, CDX2, and beta-catenin in all cases.
  • Prostatic urothelial-type adenocarcinoma is a rare aggressive cancer arising in the prostate.
  • The differential diagnosis includes conventional prostatic mucinous adenocarcinoma and secondary infiltration from a colonic or bladder adenocarcinoma.
  • Immunohistochemistry for prostate specific antigen, prostate specific acid phosphatase, and high molecular weight cytokeratin along with morphology can help rule out conventional prostate carcinoma. beta-catenin, CDX2, and clinical studies are needed to rule out colonic adenocarcinoma.
  • As prostatic urothelial-type adenocarcinoma is entirely analogous to bladder adenocarcinoma in both, its morphology and immunophenotype, only clinical studies or in some cases pathologic examination of the cystoprostatectomy specimen can exclude infiltration from a primary bladder adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / diagnosis. Mucins / analysis. Prostatic Neoplasms / diagnosis. Urothelium / pathology
  • [MeSH-minor] Acid Phosphatase. Aged. Aged, 80 and over. Cell Differentiation. Diagnosis, Differential. Follow-Up Studies. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Prostate-Specific Antigen / analysis. Protein Tyrosine Phosphatases / analysis. Time Factors. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721186.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Mucins; 0 / beta Catenin; EC 3.1.3.2 / Acid Phosphatase; EC 3.1.3.2 / prostatic acid phosphatase; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


84. Chua CW, Chiu YT, Yuen HF, Chan KW, Wang X, Ling MT, Wong YC: Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma. APMIS; 2010 Dec;118(12):918-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma.
  • One of the common features in advanced prostate cancer is bone metastasis.
  • In this study, we investigated the clinical relevance of a bone factor, MSX2, in predicting the metastatic ability of prostate adenocarcinoma.
  • Evaluation of MSX2 expression was performed using prostate cell lines as well as patient specimens.
  • A sharp decrease in MSX2 was found in primary prostate cancer cells, 22Rv1, when compared with the non-malignant counterparts, followed by a gradual increase in more aggressive prostate cancer cell lines.
  • Interestingly, the MSX2 protein was upregulated and predominantly expressed in the nucleus in aggressive prostate cancer cell line, C4-2b, compared with the less aggressive 22Rv1.
  • Consistent with the in vitro results, MSX2 nuclear expression was significantly higher in nodular hyperplasia when compared with high-grade prostatic intraepithelial neoplasia (PIN), while MSX2 nuclear expression in prostate adenocarcinoma was higher than that in high-grade PIN.
  • Taken together, MSX2 may serve as a potential biomarker in predicting primary prostate tumors with higher metastatic capability.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Prostatic Hyperplasia / metabolism. Prostatic Intraepithelial Neoplasia / metabolism. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal Compilation © 2010 APMIS.
  • (PMID = 21091772.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / MSX2 protein
  •  go-up   go-down


85. Tchan MC, George M, Thomas M: Metastatic prostate cancer mimicking primary osteosarcoma of the jaw: an infrequent clinical case. South Med J; 2008 Jun;101(6):657-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic prostate cancer mimicking primary osteosarcoma of the jaw: an infrequent clinical case.
  • Prostate cancer metastasizing to the mandible is a rare occurrence.
  • Radiological investigation demonstrated a lesion within the left mandibular ramus, and subsequent biopsy confirmed the diagnosis of metastatic prostate cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Mandibular Neoplasms / diagnosis. Mandibular Neoplasms / secondary. Osteosarcoma / diagnosis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / blood. Biopsy. Diagnosis, Differential. Humans. Immunoenzyme Techniques. Male. Mandible / pathology. Prostate-Specific Antigen / blood. Tomography, X-Ray Computed


86. Lee JL, Kim JE, Ahn JH, Lee DH, Lee J, Kim CS, Hong JH, Hong B, Song C, Ahn H: Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat; 2010 Mar;42(1):12-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea.
  • PURPOSE: To assess the efficacy and safety of treating Korean patients with metastatic hormone-refractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.
  • MATERIALS AND METHODS: This was a retrospective cohort study performed in 98 patients with metastatic HRPC between October 2003 and April 2008.
  • Tumor response was evaluated in 13 patients, 4 patients achieved PR, and 5 patients had SD with a response rate of 31%.
  • CONCLUSION: This chemotherapy regimen (docetaxel every 3 weeks plus prednisolone daily) demonstrated a strong response in Korean patients with metastatic HRPC, while the toxicity profile was manageable and similar to that observed in Western patients.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3742-8 [19470933.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2506-13 [10561316.001]
  • [Cites] Curr Opin Oncol. 2009 May;21(3):260-5 [19363343.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):436-41 [19190633.001]
  • [Cites] Curr Opin Hematol. 2009 Jan;16(1):48-52 [19057204.001]
  • [Cites] Yonsei Med J. 2008 Oct 31;49(5):775-82 [18972598.001]
  • [Cites] Clin Cancer Res. 2008 Oct 1;14(19):6270-6 [18829508.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):2959-65 [18565882.001]
  • [Cites] Jpn J Clin Oncol. 2008 May;38(5):365-72 [18417502.001]
  • [Cites] BJU Int. 2008 Mar;101 Suppl 2:11-5 [18307687.001]
  • [Cites] J Clin Oncol. 2008 Mar 1;26(7):1148-59 [18309951.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):631-7 [17520252.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):242-5 [18182665.001]
  • [Cites] Drugs. 2007;67(8):1109-24 [17521214.001]
  • [Cites] Clin Pharmacokinet. 1999 Feb;36(2):99-114 [10092957.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1756-64 [8656243.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1513-20 [15470214.001]
  • [Cites] N Engl J Med. 2004 Oct 7;351(15):1502-12 [15470213.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):449-54 [12598352.001]
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3683-90 [12202670.001]
  • [Cites] CA Cancer J Clin. 2002 May-Jun;52(3):154-79 [12018929.001]
  • [Cites] Curr Opin Oncol. 2009 Jul;21(4):297-302 [19509500.001]
  • (PMID = 20369046.001).
  • [ISSN] 2005-9256
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2848748
  • [Keywords] NOTNLM ; Chemotherapy / Docetaxel / Febrile neutropenia / Hormone-refractory prostate cancer / Prednisolone
  •  go-up   go-down


87. Sciarra A, Lichtner M, Autran GA, Mastroianni C, Rossi R, Mengoni F, Cristini C, Gentilucci A, Vullo V, Di Silverio F: Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients. Prostate; 2007 Jan 1;67(1):1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of circulating blood dendritic cell subsets DC123+ (lymphoid) and DC11C+ (myeloid) in prostate adenocarcinoma patients.
  • PURPOSE: We verified whether prostate adenocarcinoma produces specific modifications in DC subsets count.
  • METHODS: Twenty-one untreated prostate adenocarcinomas were divided on the basis of clinical stage in localized and metastatic disease.
  • RESULTS: We showed a statistically significant reduction in pDCs count in prostate cancer population when compared to healthy controls (P = 0.002).
  • Comparing each clinical stage with healthy controls, significant differences were found between controls and the metastatic group in both pDCs and mDCs (P = 0.005 and P = 0.023 respectively) but not between controls and the localized group (P = 0.055 and P = 0.829 respectively).
  • CONCLUSIONS: We showed that DCs count in PB is significantly affected by prostate adenocarcinoma progression in a metastatic disease.
  • [MeSH-major] Adenocarcinoma / pathology. Dendritic Cells / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 17075798.001).
  • [ISSN] 1097-0045
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Pruthi RS, Hubbard JS, Kouba E, Wallen E: Androgen-independent prostate cancer treated with resection of the solitary metastatic site. Urol Int; 2007;79(4):371-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen-independent prostate cancer treated with resection of the solitary metastatic site.
  • The concept of resection of a solitary metastatic lesion is quite foreign in prostate cancer, as metastases to regional lymph nodes or to other distant sites are most likely suggestive of disseminated disease.
  • The current report demonstrates a very unique case, in whom excision of a solitary pulmonary metastasis has resulted in continued undetectable prostate-specific antigen values over 3 years after resection.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Prostate-Specific Antigen / blood. Prostatic Neoplasms / surgery


89. Tan WW: Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control; 2006 Jul;13(3):194-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel agents and targets in managing patients with metastatic prostate cancer.
  • BACKGROUND: Docetaxel has recently been found to improve survival in patients with metastatic androgen-independent prostate cancer (AIPC).
  • METHODS: Clinically relevant articles focusing on chemotherapy drugs for metastatic prostate cancer and their mechanism of action and efficacy were reviewed from January 2004 through April 2006.
  • CONCLUSIONS: Docetaxel should be considered for first-line treatment of metastatic AIPC.
  • [MeSH-major] Adenocarcinoma / therapy. Bone Neoplasms / therapy. Prostatic Neoplasms / therapy


90. Dorsi MJ, Zenonos G, Hsu W, Huang J: Dural prostate adenocarcinoma metastasis with subdural hematoma mimicking the appearance of an epidural hematoma. Clin Neurol Neurosurg; 2010 Jul;112(6):501-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dural prostate adenocarcinoma metastasis with subdural hematoma mimicking the appearance of an epidural hematoma.
  • Prostatic adenocarcinoma presenting as metastatic disease to the nervous system is a rare pathologic entity and has infrequently been reported over the last several years.
  • Here we describe the clinical presentation, evaluation and surgical intervention of a patient with a dural prostate carcinoma metastasis with chronic subdural hematoma mimicking an epidural hematoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Brain Neoplasms / secondary. Hematoma, Epidural, Spinal / pathology. Hematoma, Subdural / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20347213.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


91. MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL: Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate; 2005 Jul 1;64(2):139-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
  • BACKGROUND: Hepatocyte growth factor/scatter factor (HGF/SF) facilitates intercellular communication between the epithelial carcinoma and its surrounding stromal tissue during metastatic invasion through interaction with its proto-oncogenic receptor, Met, found on carcinoma cells.
  • This study utilizes the C31/Tag transgenic mouse prostate cancer cell line model in an attempt to characterize the interaction between HGF/SF and Met on the metastatic potential of prostate cancer.
  • METHODS: Exogenous HGF was supplied to the prostate adenocarcinoma cell line (Pr-14) and metastatic cell line (Pr-14c) to evaluate mitogenicity by proliferation assays, morphological characteristics on an extracellular matrix substrate, and motogenic properties using the scatter assay, invasion chambers, and zymogram studies to analyze secretory enzymes produced by the cell lines.
  • Pr-14 cells have an increased growth rate following HGF/SF treatment, whereas the metastatic Pr-14c cells show little change.
  • Morphological studies of Pr-14c cells on extracellular matrix demonstrate negligible changes when compared to the tubular formation of Pr-14 cells after HGF/SF stimulation.
  • Motility studies of the metastatic cells following HGF/SF treatment reveal a potentially faulty signaling pathway downstream of Met activation in the metastatic prostate cells.
  • CONCLUSIONS: Our studies suggest that proliferation, invasion, and cell morphological characteristics may be induced independently from the HGF/SF-Met pathway in C31/Tag metastatic prostate cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Hepatocyte Growth Factor / genetics. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins c-met / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15678502.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


92. Gomes AC, Neto PJ, de Oliveira e Silva ED, Sávio E, Neto IC: Metastatic adenocarcinoma involving several bones of the body and the cranio-maxillofacial region: a case report. J Can Dent Assoc; 2009 Apr;75(3):211-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma involving several bones of the body and the cranio-maxillofacial region: a case report.
  • These metastatic tumours are most often located in the mandible, and the majority of these in the molar region.
  • The most common primary sources of metastatic tumours found in the oral region are the lung, kidney and prostate gland for the males, and the breast, genital organs and kidneys for females.
  • We present the case of a 51-year-old woman with metastatic adenocarcinoma involving the condyle and mandible, and other bones of the body.
  • [MeSH-major] Adenocarcinoma / secondary. Mandibular Neoplasms / secondary. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356321.001).
  • [ISSN] 1488-2159
  • [Journal-full-title] Journal (Canadian Dental Association)
  • [ISO-abbreviation] J Can Dent Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


93. Eaton CL, Colombel M, van der Pluijm G, Cecchini M, Wetterwald A, Lippitt J, Rehman I, Hamdy F, Thalman G: Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate; 2010 Jun 01;70(8):875-82
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer.
  • BACKGROUND: Tumour cells with a stem cell-like phenotype have recently been identified in prostate tumors and it has been suggested that this population may be responsible for the diversity of cell types within tumors and also for the initiation of metastases.
  • In this study we have, for the first time, assessed matched primary and bone marrow biopsies from prostate cancer patients for the distribution of cells carrying these and a number of other putative stem cell markers.
  • METHODS: Eleven matched (primary and bone metastasis) specimens from prostate cancer patients were assessed for the presence of cd133, cd44, alpha2beta1 integrin, CXCR4, c-met, alpha6 integrin, and nestin using immunohistochemistry and stain intensity and distribution scored.
  • CONCLUSIONS: In established metastases no single or combination of marker expression profiles identify the established metastatic phenotype, although cd44 expression was shown to be more frequent in metastases that in primary cancers.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplastic Stem Cells / cytology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Bone and Bones / metabolism. Bone and Bones / pathology. Cell Count. Humans. Immunohistochemistry. Integrins / metabolism. Intermediate Filament Proteins / metabolism. Male. Nerve Tissue Proteins / metabolism. Nestin. Prostate / metabolism. Prostate / pathology


94. Rozková D, Tiserová H, Fucíková J, Last'ovicka J, Podrazil M, Ulcová H, Budínský V, Prausová J, Linke Z, Minárik I, Sedivá A, Spísek R, Bartůnková J: FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. Clin Immunol; 2009 Apr;131(1):1-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
  • We review experimental basis and key concepts of combined chemo-immunotherapy and document its principles in the case report of patient with hormone refractory metastatic prostate cancer with sinister prognosis.
  • More than four hundred prostate cancer patients have been treated with DC-based immunotherapy and tumor-specific immune responses have been reported in two-thirds of them.
  • Prostate cancer patients have elevated numbers of circulating and tumor infiltrating Tregs and there is evidence that Tregs increase tumor growth in vivo.
  • After obtaining IRB approval, we started regular vaccinations with dendritic cells (DCs) loaded with killed prostate cancer cells.
  • DC-based vaccination induced prostate cancer cell-specific immune response.
  • Combined chemo-immunotherapy consisting of alternate courses of chemotherapy and vaccination with mature DCs pulsed with LNCap prostate cancer cell line led to the marked improvement in the clinical and laboratory presentation and to the decrease of PSA levels by more than 90%.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / therapeutic use. Immunotherapy / methods. Prostatic Neoplasms / therapy


95. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, Huard J, Lieberman JR: Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res; 2005 Dec;20(12):2189-99
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
  • The purpose of this study was to evaluate the role of BMPs on the formation of metastatic prostate cancer lesions to bone.
  • INTRODUCTION: Prostate adenocarcinoma is the leading cause of cancer in North American men.
  • Although BMPs have been found to be expressed in multiple oncogenic cell lines, their role in the formation of metastatic osteoblastic lesions remains uncharacterized.
  • We hypothesized that BMPs influence the development of metastatic osteoblastic lesions associated with prostate cancer.
  • MATERIALS AND METHODS: Western blot analysis and RT-PCR was used to determine BMP receptor expression on osteoblastic prostate cancer cell lines LAPC-4 and LAPC-9.
  • RESULTS: We determined that BMP receptor mRNA and protein was expressed on osteoblastic prostate cancer cell lines LAPC-4 and LAPC-9.
  • In vitro studies showed that BMP-2 and -7 stimulated cellular migration and invasion of prostate cancer cells in a dose-dependent fashion, although BMP-4 had no effect.
  • Formation of osteoblastic lesions was inhibited by overexpression of noggin by prostate cancer cells transduced with a retrovirus containing the cDNA for noggin.
  • CONCLUSIONS: BMPs are critical in the formation of the osteoblastic lesions associated with prostate cancer metastases, and future treatment strategies that inhibit local BMP activity may reduce the formation and progression of osteoblastic lesions.
  • [MeSH-major] Bone Morphogenetic Proteins / metabolism. Osteoblasts / pathology. Prostatic Neoplasms / pathology

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16294272.001).
  • [ISSN] 0884-0431
  • [Journal-full-title] Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • [ISO-abbreviation] J. Bone Miner. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 10303901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP2 protein, human; 0 / BMP4 protein, human; 0 / BMP7 protein, human; 0 / Bmp2 protein, mouse; 0 / Bmp4 protein, mouse; 0 / Bone Morphogenetic Protein 2; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Protein 7; 0 / Bone Morphogenetic Proteins; 0 / Carrier Proteins; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta; 148294-77-3 / noggin protein; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type I; EC 2.7.11.30 / Bone Morphogenetic Protein Receptors, Type II
  •  go-up   go-down


96. Shrivastava V, Christensen R, Poggi MM: Prostate cancer metastatic to the external auditory canals. Clin Genitourin Cancer; 2007 Jun;5(5):341-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate cancer metastatic to the external auditory canals.
  • A 58-year-old white man with prostate-specific antigen (PSA) level of 6 ng/mL, a Gleason score of 6 (3+3), and T2a adenocarcinoma of the prostate underwent prostatectomy.
  • The PSA continued to increase, and the patient developed bone-only metastatic disease.
  • Six months later, he presented with bilateral hearing loss and was found to have pathologic and radiographic evidence of metastatic prostate cancer to the external auditory canals.
  • [MeSH-major] Adenocarcinoma / secondary. Ear Canal / pathology. Ear Neoplasms / secondary. Prostatic Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Male. Middle Aged. Prostate-Specific Antigen / blood. Prostatectomy


97. Salamanca JI, Murrieta C, Jara J, Munoz-Blanco JL, Alvarez F, De Villoria JG, Hernandez C: Occipital condyle syndrome guiding diagnosis to metastatic prostate cancer. Int J Urol; 2006 Jul;13(7):1022-4
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occipital condyle syndrome guiding diagnosis to metastatic prostate cancer.
  • OCS diagnosis occurred, in all cases described in the published literature, when metastatic prostate cancer (MPC) was previously known.
  • [MeSH-major] Adenocarcinoma / secondary. Occipital Bone. Prostatic Neoplasms / pathology. Skull Base Neoplasms / secondary

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16882081.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


98. Lloyd A, Penson D, Dewilde S, Kleinman L: Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis; 2008;11(2):153-9
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
  • Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life.
  • The present study aims to elicit patient preferences with respect to the attributes of treatments for metastatic prostate cancer through a discrete choice experiment (DCE) questionnaire.
  • Men with recently diagnosed localized prostate cancer were asked to envisage that they had metastatic disease when completing a survey.
  • As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important.
  • Survival gains should be considered alongside side effects when discussing treatment options in metastatic disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Androgen Antagonists / therapeutic use. Anilides / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Flutamide / therapeutic use. Nitriles / therapeutic use. Patient Satisfaction. Prostatic Neoplasms / drug therapy. Tosyl Compounds / therapeutic use

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17637761.001).
  • [ISSN] 1476-5608
  • [Journal-full-title] Prostate cancer and prostatic diseases
  • [ISO-abbreviation] Prostate Cancer Prostatic Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Tosyl Compounds; 76W6J0943E / Flutamide; A0Z3NAU9DP / bicalutamide
  •  go-up   go-down


99. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ: Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol; 2008 May 20;26(15):2544-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.
  • PURPOSE: Pain from castration-refractory prostate cancer (CRPC) bone metastases is a common event.
  • Eligible patients had progressive CRPC adenocarcinoma of the prostate, an Eastern Cooperative Oncology Group performance status of 0 to 2, and adequate hematologic, renal, and hepatic functions.
  • Pain was inversely associated with likelihood of prostate-specific antigen decline, objective response, and time to bone progression.
  • CONCLUSION: This analysis demonstrates that pain is a statistically significant predictor of overall survival in men with metastatic CRPC.
  • [MeSH-major] Adenocarcinoma / mortality. Bone Neoplasms / mortality. Neoplasms, Hormone-Dependent / mortality. Orchiectomy. Pain Measurement. Prostatic Neoplasms / mortality

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Sep 1;26(25):4215-6; author reply 4216-7 [18757340.001]
  • (PMID = 18487572.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 36601
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


100. Pinto F, Brescia A, Sacco E, Volpe A, Gardi M, Gulino G, Bassi P: Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature. Arch Ital Urol Androl; 2009 Dec;81(4):212-4
Hazardous Substances Data Bank. BICALUTAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated intravascular coagulation secondary to metastatic prostate cancer: case report and review of the literature.
  • Disseminated intravascular coagulation (DIC) is the most frequent coagulation disorder associated with metastatic prostate cancer.
  • We report a case of a 60-year-old white man who was admitted in our department with ecchymoses and haematuria secondary to a DIC associated with metastatic prostate cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20608143.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EFY6W0M8TG / Leuprolide
  • [Number-of-references] 27
  •  go-up   go-down






Advertisement